AWARD/CONTRACT

1. THIS CONTRACT IS A RATED ORDER UNDER DPAS (15 CFR 700)


3. EFFECTIVE DATE

4. REQUIREMENT/PURCHASE REQUEST/PROJECT NO.

5. ISSUED BY

6. ADMINISTERED BY

7. NAME AND ADDRESS OF CONTRACTOR

8. DELIVERY

9. DISCOUNT FOR PROMPT PAYMENT

10. SUBMIT INVOICES

11. SHIP TO/MARK FOR

12. PAYMENT WILL BE MADE BY

13. AUTHORITY FOR USING OTHER THAN FULL AND OPEN COMPETITION:

14. ACCOUNTING AND APPROPRIATION DATA

15A. ITEM NO.

15B. SUPPLIES/SERVICES

15C. QUANTITY

15D. UNIT

15E. UNIT PRICE

15F. AMOUNT

15G. TOTAL AMOUNT OF CONTRACT

16. TABLE OF CONTENTS

PART I - THE SCHEDULE

PART II - CONTRACT CLAUSES

PART III - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACH.

PART IV - REPRESENTATIONS AND INSTRUCTIONS

PART V - REPRESENTATIONS, CERTIFICATIONS AND OTHER STATEMENTS OF OFFERORS

PART VI - EVALUATION FACTORS FOR AWARD

CONTRACT OFFICER WILL COMPLETE ITEM 17 (SEALED-BID OR NEGOTIATED PROCUREMENT) OR 18 (SEALED-BID PROCUREMENT) AS APPLICABLE

17. CONTRACTOR'S NEGOTIATED AGREEMENT

18. SEALED-BID AWARD

19. NAME AND TITLE OF SIGNER

20. NAME OF CONTRACTING OFFICER

21. NAME OF CONTRACTOR

22. DATE SIGNED

23. DATE SIGNED

24. SIGNATURE OF CONTRACTOR

25. AUTHORIZED FOR LOCAL REPRODUCTION

STANDARD FORM 26 (REV 5/2011)

PREVIOUS EDITION IS NOT USABLE

AUTHORIZED FOR LOCAL REPRODUCTION

PREVIOUS EDITION IS NOT USABLE

PUBLIC LAW 99-500

AUTHORIZED FOR LOCAL REPRODUCTION
Section A - Solicitation/Contract Form

A.1 The U.S. Army Contracting Command - Aberdeen Proving Ground (ACC-APG), Natick Division has a requirement for up to 500 million SARS-CoV-2 mRNA-1273 Vaccine doses (100 µg) in support of Joint Program Executive Office - Chemical Biological Radiological Nuclear Defense (JPEO-CBRND), the Assistant Secretary for Preparedness and Response (ASPR), and Biomedical Advanced Research and Development Authority (BARDA). All doses of mRNA-1273 Vaccine referenced herein are 100 µg doses. All doses will be delivered in a multi-dose vial with a volume sufficient for 10 doses per vial.
Section B - Supplies or Services and Prices

<table>
<thead>
<tr>
<th>ITEM NO</th>
<th>SUPPLIES/SERVICES</th>
<th>QUANTITY</th>
<th>UNIT</th>
<th>UNIT PRICE</th>
<th>AMOUNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>0001</td>
<td>SARS-CoV-2 mRNA-1273 Vaccine FFP</td>
<td></td>
<td></td>
<td></td>
<td>$0.00</td>
</tr>
<tr>
<td></td>
<td>The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP), IAW Section C, Statement of Work (SOW) and CDRLs (Exhibit A) on this contract. PROJECT: Operation Warp Speed</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| NET AMT | $0.00 |

<table>
<thead>
<tr>
<th>ITEM NO</th>
<th>SUPPLIES/SERVICES</th>
<th>QUANTITY</th>
<th>UNIT</th>
<th>UNIT PRICE</th>
<th>AMOUNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>0001AA</td>
<td>15M Doses</td>
<td>15,000,000</td>
<td>Each</td>
<td>$12.25</td>
<td>$183,750,000.00</td>
</tr>
<tr>
<td></td>
<td>FOB: Origin (Shipping Point) PURCHASE REQUEST NUMBER: 0011534693 PROJECT: Operation Warp Speed PSC CD: 6505</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| NET AMT | $183,750,000.00 |

ACRN AA
CIN: GFEB001153469300001

$183,750,000.00
<table>
<thead>
<tr>
<th>ITEM NO</th>
<th>SUPPLIES/SERVICES</th>
<th>QUANTITY</th>
<th>UNIT</th>
<th>UNIT PRICE</th>
<th>AMOUNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>0001AB</td>
<td>22M Doses</td>
<td>22,000,000</td>
<td>Each</td>
<td>$12.25</td>
<td>$269,500,000.00</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>FOB: Origin (Shipping Point)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PURCHASE REQUEST NUMBER: 0011534693</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PROJECT: Operation Warp Speed</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PSC CD: 6505</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NET AMT $269,500,000.00</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ACRN AB</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CIN: GFEBS001153469300002</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ITEM NO</th>
<th>SUPPLIES/SERVICES</th>
<th>QUANTITY</th>
<th>UNIT</th>
<th>UNIT PRICE</th>
<th>AMOUNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>0001AC</td>
<td>30M Doses</td>
<td>30,000,000</td>
<td>Each</td>
<td>$12.25</td>
<td>$367,500,000.00</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>FOB: Destination</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PURCHASE REQUEST NUMBER: 0011534693</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PROJECT: Operation Warp Speed</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PSC CD: 6505</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NET AMT $367,500,000.00</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ACRN AA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CIN: GFEBS001153469300003</td>
</tr>
<tr>
<td>ITEM NO</td>
<td>SUPPLIES/SERVICES</td>
<td>QUANTITY</td>
<td>UNIT</td>
<td>UNIT PRICE</td>
<td>AMOUNT</td>
</tr>
<tr>
<td>---------</td>
<td>-------------------</td>
<td>------------</td>
<td>------</td>
<td>------------</td>
<td>------------</td>
</tr>
<tr>
<td>0001AD</td>
<td>33M Doses</td>
<td>33,000,000</td>
<td>Each</td>
<td>$12.25</td>
<td>$404,250,000.00</td>
</tr>
<tr>
<td></td>
<td>FFP</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>FOB: Destination</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PURCHASE REQUEST NUMBER: 0011534693</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PROJECT: Operation Warp Speed</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PSC CD: 6505</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

| NET AMT | $404,250,000.00 |

ACRN AA
CIN: GFEBS001153469300004

---

<table>
<thead>
<tr>
<th>ITEM NO</th>
<th>SUPPLIES/SERVICES</th>
<th>QUANTITY</th>
<th>UNIT</th>
<th>UNIT PRICE</th>
<th>AMOUNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>0002</td>
<td>Vendor Managed Inventory</td>
<td>1</td>
<td>Job</td>
<td>$0.00 TBN</td>
<td>$0.00</td>
</tr>
<tr>
<td></td>
<td>FFP</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>a. The contractor shall secure, manage and maintain storage for up to 100M doses of mRNA-1273 vaccine and deliver to the designated government facility in accordance with Section F.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>b. [D] (4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>FOB: Destination</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PROJECT: Operation Warp Speed</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PSC CD: 6505</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

| NET AMT | $0.00 |

ITEM NO 0003
SUPPLIES/SERVICES EUA or BLA Incentive
QUANTITY
UNIT FFP
UNIT PRICE $3.00
AMOUNT $45,000,000

EUA or BLA Incentive
FFP
This is an incentive CLIN and will be earned only if an Emergency Use Authorization (EUA) or Biologics License Application (BLA) is obtained no later than 31 January 2021.
PROJECT: Operation Warp Speed

NET AMT $0.00

ITEM NO 0003AA
SUPPLIES/SERVICES EUA or BLA Incentive
QUANTITY 15,000,000
UNIT Each
UNIT PRICE $3.00
AMOUNT $45,000,000

FOB: Destination
PSC CD: 6505

NET AMT $45,000,000
<table>
<thead>
<tr>
<th>ITEM NO</th>
<th>SUPPLIES/SERVICES</th>
<th>QUANTITY</th>
<th>UNIT</th>
<th>UNIT PRICE</th>
<th>AMOUNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>0003AB</td>
<td>EUA or BLA Incentive</td>
<td>22,000,000</td>
<td>Each</td>
<td>$3.00</td>
<td>$66,000,000.00</td>
</tr>
<tr>
<td></td>
<td>FFP</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>If earned, this incentive shall be paid at final acceptance of subCLIN 0001AB.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>FOB: Destination</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PSC CD: 6505</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NET AMT</td>
<td></td>
<td></td>
<td></td>
<td>$66,000,000.00</td>
</tr>
<tr>
<td>0003AC</td>
<td>EUA or BLA Incentive</td>
<td>30,000,000</td>
<td>Each</td>
<td>$3.00</td>
<td>$90,000,000.00</td>
</tr>
<tr>
<td></td>
<td>FFP</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>If earned, this incentive shall be paid at final acceptance of subCLIN 0001AC.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>FOB: Destination</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PSC CD: 6505</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NET AMT</td>
<td></td>
<td></td>
<td></td>
<td>$90,000,000.00</td>
</tr>
<tr>
<td>0003AD</td>
<td>EUA or BLA Incentive</td>
<td>33,000,000</td>
<td>Each</td>
<td>$3.00</td>
<td>$99,000,000.00</td>
</tr>
<tr>
<td></td>
<td>FFP</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>If earned, this incentive shall be paid at final acceptance of subCLIN 0001AD.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>FOB: Destination</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PSC CD: 6505</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NET AMT</td>
<td></td>
<td></td>
<td></td>
<td>$99,000,000.00</td>
</tr>
<tr>
<td>ITEM NO</td>
<td>SUPPLIES/SERVICES</td>
<td>QUANTITY</td>
<td>UNIT</td>
<td>UNIT PRICE</td>
<td>AMOUNT</td>
</tr>
<tr>
<td>---------</td>
<td>---------------------------</td>
<td>----------</td>
<td>------</td>
<td>------------</td>
<td>--------</td>
</tr>
<tr>
<td>0004</td>
<td>Technical Data</td>
<td>1</td>
<td>Job</td>
<td></td>
<td>NSP</td>
</tr>
<tr>
<td></td>
<td>FFP</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The contractor shall deliver technical Data IAW Contract Data Requirements List (CDRL) IAW deliveries in Section C.4 and Section J, Exhibit A.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>FOB: Destination</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PROJECT: Operation Warp Speed</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PSC CD: 6505</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>NET AMT</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1001</td>
<td>SARS-CoV-2 mRNA-1273 Vaccine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OPTION</td>
<td>FFP</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP), IAW Section C, Statement of Work (SOW) and CDRLs (Exhibit A) on this contract</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PROJECT: Operation Warp Speed</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>NET AMT</strong></td>
<td></td>
<td></td>
<td></td>
<td>$0.00</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
ITEM NO | SUPPLIES/SERVICES | QUANTITY | UNIT | UNIT PRICE | AMOUNT
--- | --- | --- | --- | --- | ---
1001AA | 33.2M Doses FFP | 33,200,000 | Each | $16.50 | $547,800,000.00

a. If executed, the option shall be awarded upon EUA or no later than [D] (4) .
b. The government shall provide [D] (4) notification to exercise the option.

FOB: Destination
PROJECT: Operation Warp Speed
PSC CD: 6505

---

ITEM NO | SUPPLIES/SERVICES | QUANTITY | UNIT | UNIT PRICE | AMOUNT
--- | --- | --- | --- | --- | ---
1001AB | 33.4M Doses FFP | 33,400,000 | Each | $16.50 | $551,100,000.00

a. If executed, the option shall be awarded upon EUA or no later than [D] (4) .
b. The government shall provide [D] (4) notification to exercise the option.

FOB: Destination
PROJECT: Operation Warp Speed
PSC CD: 6505

---

NET AMT | $547,800,000.00
---

NET AMT | $551,100,000.00
<table>
<thead>
<tr>
<th>ITEM NO</th>
<th>SUPPLIES/SERVICES</th>
<th>QUANTITY</th>
<th>UNIT</th>
<th>UNIT PRICE</th>
<th>AMOUNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>1001AC</td>
<td>33.4M Doses</td>
<td>33,400,000</td>
<td>Each</td>
<td>$16.50</td>
<td>$551,100,000.00</td>
</tr>
</tbody>
</table>

**OPTION**

- If executed, the option shall be awarded upon EUA or no later than [b] [4].
- The government shall provide [b] [4] notification to exercise the option.

FOB: Destination
PROJECT: Operation Warp Speed
PSC CD: 6505

---

| NET AMT | $551,100,000.00 |

<table>
<thead>
<tr>
<th>ITEM NO</th>
<th>SUPPLIES/SERVICES</th>
<th>QUANTITY</th>
<th>UNIT</th>
<th>UNIT PRICE</th>
<th>AMOUNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>1002</td>
<td>Vendor Managed Inventory</td>
<td>1</td>
<td>Job</td>
<td>$0.00</td>
<td>TBN</td>
</tr>
</tbody>
</table>

**OPTION**

- The contractor shall secure, manage and maintain storage for up to 100M doses of mRNA-1273 vaccine and deliver to the designated government facility in accordance with Section F.
- [b] [4]

FOB: Destination
PROJECT: Operation Warp Speed
PSC CD: 6505

---

<p>| NET AMT | $0.00 |</p>
<table>
<thead>
<tr>
<th>ITEM NO</th>
<th>SUPPLIES/SERVICES</th>
<th>QUANTITY</th>
<th>UNIT</th>
<th>UNIT PRICE</th>
<th>AMOUNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>2001</td>
<td>SARS-CoV-2 mRNA-1273 Vaccine</td>
<td></td>
<td></td>
<td></td>
<td>$0.00</td>
</tr>
<tr>
<td>OPTION</td>
<td>FFP</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP), IAW Section C, Statement of Work (SOW) and CDRLs (Exhibit A) on this contract.

PROJECT: Operation Warp Speed

---

<table>
<thead>
<tr>
<th>ITEM NO</th>
<th>SUPPLIES/SERVICES</th>
<th>QUANTITY</th>
<th>UNIT</th>
<th>UNIT PRICE</th>
<th>AMOUNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>2001AA</td>
<td>33.4M Doses</td>
<td>33,400,000</td>
<td>Each</td>
<td>$16.50</td>
<td>$551,100,000</td>
</tr>
<tr>
<td>OPTION</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

a. If executed, the option shall be awarded upon EUA or no later than [D] (4).
b. The government shall provide [D] (4) notification to exercise the option.

FOB: Destination

PROJECT: Operation Warp Speed

PSC CD: 6505

---

NET AMT $0.00

NET AMT $551,100,000.00
<table>
<thead>
<tr>
<th>ITEM NO</th>
<th>SUPPLIES/SERVICES</th>
<th>QUANTITY</th>
<th>UNIT</th>
<th>UNIT PRICE</th>
<th>AMOUNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>2001AB</td>
<td>33.4M Doses</td>
<td>33,400,000</td>
<td>Each</td>
<td>$16.50</td>
<td>$551,100,000</td>
</tr>
</tbody>
</table>

**OPTION**

- a. If executed, the option shall be awarded upon EUA or no later than \(b)(4)\.
- b. The government shall provide \(b)(4)\ notification to exercise the option.

**FOB**: Destination

**PROJECT**: Operation Warp Speed

**PSC CD**: 6505

---

<table>
<thead>
<tr>
<th>NET AMT</th>
<th>$551,100,000.00</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>ITEM NO</th>
<th>SUPPLIES/SERVICES</th>
<th>QUANTITY</th>
<th>UNIT</th>
<th>UNIT PRICE</th>
<th>AMOUNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>2001AC</td>
<td>33.2M Doses</td>
<td>33,200,000</td>
<td>Each</td>
<td>$16.50</td>
<td>$547,800,000</td>
</tr>
</tbody>
</table>

**OPTION**

- a. If executed, the option shall be awarded upon EUA or no later than \(b)(4)\.
- b. The government shall provide \(b)(4)\ notification to exercise the option.

**FOB**: Destination

**PROJECT**: Operation Warp Speed

**PSC CD**: 6505

---

<table>
<thead>
<tr>
<th>NET AMT</th>
<th>$547,800,000.00</th>
</tr>
</thead>
<tbody>
<tr>
<td>ITEM NO</td>
<td>SUPPLIES/SERVICES</td>
</tr>
<tr>
<td>--------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>2002</td>
<td>Vendor Managed Inventory</td>
</tr>
<tr>
<td>OPTION</td>
<td>FFP</td>
</tr>
<tr>
<td></td>
<td>a. The contractor shall secure, manage and maintain storage for up to 100M doses of mRNA-1273 vaccine and deliver to the designated government facility in accordance with Section F.</td>
</tr>
<tr>
<td></td>
<td>b. FOB: Destination</td>
</tr>
<tr>
<td></td>
<td>PROJECT: Operation Warp Speed</td>
</tr>
<tr>
<td></td>
<td>PSC CD: 6505</td>
</tr>
<tr>
<td></td>
<td>NET AMT</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ITEM NO</th>
<th>SUPPLIES/SERVICES</th>
<th>QUANTITY</th>
<th>UNIT</th>
<th>UNIT PRICE</th>
<th>AMOUNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>3001</td>
<td>SARS-CoV-2 mRNA-1273 Vaccine</td>
<td></td>
<td></td>
<td>$0.00</td>
<td></td>
</tr>
<tr>
<td>OPTION</td>
<td>FFP</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP), IAW Section C, Statement of Work (SOW) and CDRLs (Exhibit A) on this contract.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PROJECT: Operation Warp Speed</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NET AMT</td>
<td></td>
<td></td>
<td>$0.00</td>
<td></td>
</tr>
<tr>
<td>ITEM NO</td>
<td>SUPPLIES/SERVICES</td>
<td>QUANTITY</td>
<td>UNIT</td>
<td>UNIT PRICE</td>
<td>AMOUNT</td>
</tr>
<tr>
<td>---------</td>
<td>-------------------</td>
<td>------------</td>
<td>------</td>
<td>------------</td>
<td>--------------</td>
</tr>
<tr>
<td>3001AA</td>
<td>33.4M Doses</td>
<td>33,400,000</td>
<td>Each</td>
<td>$16.50</td>
<td>$551,100,000</td>
</tr>
</tbody>
</table>

**OPTION**

- **33.4M Doses**
- **FFP**
  - a. If executed, the option shall be awarded upon EUA or no later than [D] (4).
  - b. The government shall provide [D] (4) notification to exercise the option.

**FOB: Destination**

**PROJECT: Operation Warp Speed**

**PSC CD: 6505**

<table>
<thead>
<tr>
<th>NET AMT</th>
<th>$551,100,000.00</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>ITEM NO</th>
<th>SUPPLIES/SERVICES</th>
<th>QUANTITY</th>
<th>UNIT</th>
<th>UNIT PRICE</th>
<th>AMOUNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>3001AB</td>
<td>33.4M Doses</td>
<td>33,400,000</td>
<td>Each</td>
<td>$16.50</td>
<td>$551,100,000</td>
</tr>
</tbody>
</table>

**OPTION**

- **33.4M Doses**
- **FFP**
  - a. If executed, the option shall be awarded upon EUA or no later than [D] (4).
  - b. The government shall provide [D] (4) notification to exercise the option.

**FOB: Destination**

**PROJECT: Operation Warp Speed**

**PSC CD: 6505**

<table>
<thead>
<tr>
<th>NET AMT</th>
<th>$551,100,000.00</th>
</tr>
</thead>
<tbody>
<tr>
<td>ITEM NO</td>
<td>SUPPLIES/SERVICES</td>
</tr>
<tr>
<td>---------</td>
<td>-------------------</td>
</tr>
<tr>
<td>3001AC</td>
<td>33.2M Doses</td>
</tr>
</tbody>
</table>

**OPTION**

- a. If executed, the option shall be awarded upon EUA or no later than **[D][4]**.
- b. The government shall provide **[D][4]** notification to exercise the option.

**FOB: Destination**

**PROJECT: Operation Warp Speed**

**PSC CD: 6505**

---

| NET AMT | $547,800,000.00 |

<table>
<thead>
<tr>
<th>ITEM NO</th>
<th>SUPPLIES/SERVICES</th>
<th>QUANTITY</th>
<th>UNIT</th>
<th>UNIT PRICE</th>
<th>AMOUNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>3002</td>
<td>Vendor Managed Inventory</td>
<td>1</td>
<td>Job</td>
<td>$0.00</td>
<td>$0.00 TBN</td>
</tr>
</tbody>
</table>

**OPTION**

The contractor shall secure, manage and maintain storage for up to 100M doses of mRNA-1273 vaccine and deliver to the designated government facility in accordance with Section F.

**FOB: Destination**

**PROJECT: Operation Warp Speed**

**PSC CD: 6505**

---

<p>| NET AMT | $0.00 |</p>
<table>
<thead>
<tr>
<th>ITEM NO</th>
<th>SUPPLIES/SERVICES</th>
<th>QUANTITY</th>
<th>UNIT</th>
<th>UNIT PRICE</th>
<th>AMOUNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>4001</td>
<td>SARS-CoV-2 mRNA-1273 Vaccine</td>
<td></td>
<td></td>
<td></td>
<td>$0.00</td>
</tr>
<tr>
<td>OPTION</td>
<td>FFP</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP), IAW Section C, Statement of Work (SOW) and CDRLs (Exhibit A) on this contract.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PROJECT: Operation Warp Speed</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| NET AMT | $0.00 |

<table>
<thead>
<tr>
<th>ITEM NO</th>
<th>SUPPLIES/SERVICES</th>
<th>QUANTITY</th>
<th>UNIT</th>
<th>UNIT PRICE</th>
<th>AMOUNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>4001AA</td>
<td>33.4M Doses</td>
<td>33,400,000</td>
<td>Each</td>
<td>$16.50</td>
<td>$551,100,000.00</td>
</tr>
<tr>
<td>OPTION</td>
<td>FFP</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>a. If executed, the option shall be awarded upon EUA or no later than [b] (4).</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>b. The government shall provide [b] (4) notification to exercise the option.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>FOB: Destination</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PROJECT: Operation Warp Speed</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PSC CD: 6505</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<p>| NET AMT | $551,100,000.00 |</p>
<table>
<thead>
<tr>
<th>ITEM NO</th>
<th>SUPPLIES/SERVICES</th>
<th>QUANTITY</th>
<th>UNIT</th>
<th>UNIT PRICE</th>
<th>AMOUNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>4001AB</td>
<td></td>
<td>33,400,000</td>
<td>Each</td>
<td>$16.50</td>
<td>$551,100,000.00</td>
</tr>
<tr>
<td>OPTION</td>
<td>33.4M Doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>FFP</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a.</td>
<td>If executed, the option shall be awarded upon EUA or no later than [D] (4).</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b.</td>
<td>The government shall provide [D] (4) notification to exercise the option.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>FOB: Destination</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PROJECT: Operation Warp Speed</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PSC CD: 6505</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NET AMT $551,100,000.00

<table>
<thead>
<tr>
<th>ITEM NO</th>
<th>SUPPLIES/SERVICES</th>
<th>QUANTITY</th>
<th>UNIT</th>
<th>UNIT PRICE</th>
<th>AMOUNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>4001AC</td>
<td></td>
<td>33,200,000</td>
<td>Each</td>
<td>$16.50</td>
<td>$547,800,000.00</td>
</tr>
<tr>
<td>OPTION</td>
<td>33.2M Doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>FFP</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a.</td>
<td>If executed, the option shall be awarded upon EUA or no later than [D] (4).</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b.</td>
<td>The government shall provide [D] (4) notification to exercise the option.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>FOB: Destination</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PROJECT: Operation Warp Speed</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PSC CD: 6505</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NET AMT $547,800,000.00
<table>
<thead>
<tr>
<th>ITEM NO</th>
<th>SUPPLIES/SERVICES</th>
<th>QUANTITY</th>
<th>UNIT</th>
<th>UNIT PRICE</th>
<th>AMOUNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>4002</td>
<td>Vendor Managed Inventory</td>
<td>1</td>
<td>Job</td>
<td>$0.00</td>
<td>$0.00</td>
</tr>
</tbody>
</table>

The contractor shall secure, manage and maintain storage for up to 100M doses of mRNA-1273 vaccine and deliver to the designated government facility in accordance with Section F.

b. [Redacted]

FOB: Destination

PROJECT: Operation Warp Speed

PSC CD: 6505

NET AMT $0.00
STATEMENT OF WORK
LARGE SCALE PRODUCTION OF SARS-CoV-2 VACCINE

C.1 SCOPE. The Department of Defense and Health and Human Services (HHS) require large scale manufacturing of vaccine doses in support of the national emergency response to the Coronavirus Disease 2019 (COVID-19) for the United States Government (USG) and the US population.

C.1.1 Background. In December 2019, a novel coronavirus now known as SARS-CoV-2 was first detected in Wuhan, Hubei Province, People’s Republic of China, causing outbreaks of the coronavirus disease COVID-19 that has now spread globally. The Secretary of Health and Human Service declared a public health emergency on January 31, 2020, under section 319 of the Public Health Service Act (42 U.S.C. 247d), in response to COVID-19. On March 1, 2020, the President of the United States, pursuant to sections 01 and 301 of the National Emergencies Act (50 U.S.C. 1601 et seq.) and consistent with section 1135 of the Social Security Act (SSA), as amended (42 U.S.C. 1320b-5), proclaimed that the COVID-19 outbreak in the United States constitutes a national emergency.

C.1.1.1 Under Operation Warp Speed (OWS), the Department of Defense and HHS are leading a whole of nation effort to ensure development of promising vaccine, diagnostic and therapeutic candidates and ensure that these medical countermeasures are available in the quantities required to reduce SARS-CoV-2 transmission, identify prior and/or current infection, and improve patient care, thereby mitigating the impact of COVID-19 on the nation and its people. The DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRD) is providing expertise and contracting support to HHS, in compliance with PL 115-92 Authorization Letter for DoD Medical Priorities, through an Interagency Agreement, signed April 23, 2020. As OWS products progress to clinical trials to evaluate the safety and efficacy of vaccines and therapeutics, it is critical that, in parallel, the USG supports large scale manufacturing so that vaccine doses or therapeutic treatment courses are immediately available for nationwide access as soon as a positive efficacy signal is obtained and the medical countermeasures are authorized for widespread use.

C.1.2 Objective: The objective of this effort is to obtain the following:

a. Base Period: Large scale manufacturing of 100 million vaccine doses
b. Option Period 1: Large scale manufacturing of 100 million vaccine doses
c. Option Period 2: Large scale manufacturing of 100 million vaccine doses
d. Option Period 3: Large scale manufacturing of 100 million vaccine doses
e. Option Period 4: Large scale manufacturing of 100 million vaccine doses

The Base Period is 9 months, with overlapping options for a total of 20 months if all options are exercised.

C.2 APPLICABLE DOCUMENTS.

C.2.1 Federal Documents:

C.2.1.1 Title 21 Code of Federal Regulations (CFR), Food and Drugs: Part 210, Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General; and, Part 211, Current Good Manufacturing Practice In Manufacturing, Processing, Packing, or Holding of Drugs; General.

C.3 REQUIREMENTS. Independently, and not as an agent of the USG, in accordance with the Proposal submitted by ModernaTX, Inc. in response to Solicitation Number W911QY20R0043, Titled, “Advanced Procurement of mRNA-1273 Vaccine for Prevention of SARS-CoV-2 Coronavirus (COVID-19)”), dated July 10, 2020 (and any subsequent USG-approved revisions thereto), the contractor shall provide all necessary services,
qualified personnel, material, equipment and facilities (not otherwise provided by the USG under the terms of this contract) to perform the specific tasks set forth below.

C.3.1 Contract Line Item Number (CLIN) 0001 - Base Period: Large Scale Manufacturing of 100 Million Vaccine Doses.

C.3.1.1 The contractor shall complete all scope required for the production, release and delivery use of 100 million Final Drug Product (FDP) doses of a SARS-CoV-2 mRNA-1273 vaccine. This shall include, the following tasks and other activities reasonably contemplated by such task:

C.3.1.1.1 Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations. Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of 12 months. (Based on FDP stability data that supports a 12-month shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC. Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.

C.3.1.1.2 cGMP manufacturing of 100 million doses fully compliant with 21 CFR 210 and 211.

C.3.1.1.3 Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated as appropriate.

C.3.1.1.4 Coordinating with FDA to establish an approved commercial vial label, carton and packaging insert (printed or electronic).

C.3.1.1.5 Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements, subject to any exceptions established by or the enforcement discretion of the FDA, including “Exemption from Certain Product Tracing and Product Identification Requirements Under Section 582 of the FD&C Act” (April 2020).

C.3.1.1.6 In coordination with the USG, the contractor shall conduct a demonstration of the vaccine shipping process prior to the first delivery of FDP doses at a time mutually agreed to by the contractor and the USG. Moderna shall provide specifications and details associated with the shipping process and containers (IAW CDRL A005) to enable the USG to adequately plan and prepare for potential distribution of the vaccine.

C.3.1.1.7 Following release of product the contractor shall, promptly deliver product to the designated delivery site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below. In the unforeseen event that a designated delivery site cannot receive product and the contractor provides storage beyond 20 days of product release, the contract will be subject to modification for acceptance purposes.

C.3.1.2 Site Visits and Audits. The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.

C.3.1.2.1 BARDA Audits. If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.

C.3.1.2.2 FDA Audits. The Contractor shall notify the Contracting Officer and Contracting Officer’s Representative (COR) within [D] [4] of a scheduled FDA audit or within [D] [4] of an ad hoc site visit or audit if the FDA does not provide advance notice. The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [D] [4] of receiving correspondence from the FDA or third party in accordance with CDRL A002. The Contractor shall
provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within [ ] of submittal of the audit report in accordance with CDRL A002.

C.3.1.2.3 FDA Interactions. The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologics for the following, but not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.

C.3.2 CLIN 1001 - Option Period 1: Large Scale Manufacturing of 100 Million Vaccine Doses.

C.3.2.1 The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine. This shall include the following tasks and other activities reasonably contemplated by such tasks:

C.3.2.1.1 Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations. Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of 12 months. (Based on FDP stability data that supports a 12-month shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC. Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.

C.3.2.1.2 cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.

C.3.2.1.3 Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated.

C.3.2.1.4 Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA.

C.3.2.1.5 Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below. To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site’s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site.

C.3.2.2 Site Visits and Audits. The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.

C.3.2.2.1 BARDA Audits. If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.

C.3.2.2.2 FDA Audits. The Contractor shall notify the Contracting Officer and COR within [ ] of a scheduled FDA audit or within [ ] of an ad hoc site visit or audit if the FDA does not provide advance notice. The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [ ] of receiving correspondence from the FDA or third party in accordance with CDRL A015. The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within [ ] of submittal of the audit report in accordance with CDRL A002.

C.3.2.2.3 FDA Interactions. The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologics for the following, but
not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.

**C.3.3 CLIN 2001 - Option Period 2: Large Scale Manufacturing of 100 Million Vaccine Doses.**

C.3.3.1 The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine. This shall include the following tasks and other activities reasonably contemplated by such tasks:

C.3.3.1.1 Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations. Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of 12 months. (Based on FDP stability data that supports a 12-month shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21 CFR 207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC. Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.

C.3.3.1.2 cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.

C.3.3.1.3 Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated as appropriate.

C.3.3.1.4 Ensuring that the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements, subject to any exceptions established by or the enforcement discretion of the FDA.

C.3.3.1.5 Following release the contractor shall deliver product to the nearest designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below. To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site’s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site.

C.3.3.2 Site Visits and Audits. The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.

C.3.3.2.1 BARDA Audits. If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.

C.3.3.2.2 FDA Audits. The Contractor shall notify the Contracting Officer and COR within [b] (4) [b] of a scheduled FDA audit or within [b] (4) [b] of an ad hoc site visit or audit if the FDA does not provide advance notice. The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [b] (4) [b] of receiving correspondence from the FDA or third party in accordance with CDRL A002. The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within [b] (4) [b] of submittal of the audit report in accordance with CDRL A002.

C.3.3.2.3 FDA Interactions. The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologics for the following, but not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.

**C.3.4 CLIN 3001 - Option Period 3: Large Scale Manufacturing of 100 Million Vaccine Doses.**
C.3.4.1 The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine. This shall include the following tasks and other activities reasonably contemplated by such tasks:

C.3.4.1.1 Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations. Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of 12 months. (Based on FDP stability data that supports a 12-month shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC. Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.

C.3.4.1.2 cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.

C.3.4.1.3 Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated.

C.3.4.1.4 Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA.

C.3.4.1.5 Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below. To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site’s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site.

C.3.4.2 Site Visits and Audits. The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.

C.3.4.2.1 BARDA Audits. If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.

C.3.4.2.2 FDA Audits. The Contractor shall notify the Contracting Officer and COR within [b] (4) of a scheduled FDA audit or within [b] (4) of an ad hoc site visit or audit if the FDA does not provide advance notice. The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [b] (4) of receiving correspondence from the FDA or third party in accordance with CDRL A015. The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within [b] (4) of submittal of the audit report in accordance with CDRL A002.

C.3.4.2.3 FDA Interactions. The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding mRNA-1273 for the following, but not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.

C.3.5 CLIN 4001 - Option Period 4: Large Scale Manufacturing of 100 Million Vaccine Doses.

C.3.5.1 The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine. This shall include the following tasks and other activities reasonably contemplated by such tasks:
C.3.5.1.1 Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations. Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of 12 months. (Based on FDP stability data that supports a 12-month shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC. Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.

C.3.5.1.2 cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.

C.3.5.1.3 Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated.

C.3.5.1.4 Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 22013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA.

C.3.5.1.5 Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below. To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site’s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site.

C.3.5.2 Site Visits and Audits. The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.

C.3.5.2.1 BARDA Audits. If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.

C.3.5.2.2 FDA Audits. The Contractor shall notify the Contracting Officer and COR within [30] days of a scheduled FDA audit or within [7] days of an ad hoc site visit or audit if the FDA does not provide advance notice. The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [30] days of receiving correspondence from the FDA or third party in accordance with CDRL A015. The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within [30] days of submittal of the audit report in accordance with CDRL A002.

C.3.5.2.3 FDA Interactions. The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologics for the following, but not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.

C.4 CLIN 0002: Data Deliverables. The contractor shall provide the following in accordance with the Contract Data Requirements List (CDRL), DD Forms 1423, provided at Appendix A.

C.4.1 Monthly Inventory Report (CDRL A003), detailing at a minimum, raw materials, Bulk mRNA, formulated LNPs, and the fill, finish, and released product.

C.4.2 Quality Management Plan. The contractor shall provide a Quality Management Plan, in accordance with CDRL A004, describing the quality policy and objectives, management review, competencies and training, process document control, feedback, evaluation, corrective action and preventive action, process improvement, measurement, and data analysis processes. The framework is normally divided into infrastructure, senior
management responsibility, resource management, lifecycle management, and quality management system evaluation.

C.4.3 Shipping Documentation (CDRL A005) for all Finished Drug Product (FDP) transferring from the contractor's fill/finish facility to a USG facility. The contractor shall obtain concurrence on planned shipment protocols prior to transport.

C.4.4 Expiring Items Report (CDRL A006) for all FDP in the USG's possession.

C.4.5 Key Personnel Listing (CDRL A007).

C.4.6 Monthly Technical Progress Report (CDRL A008), to include an Integrated Master Schedule, identifying key activities and contract status.

C.4.7 Final Technical Report (CDRL A009), documenting the work performed and results obtained for the entire contract period of performance.

C.4.8 Supply Chain Resiliency Plan (SCRP). The contractor shall provide, in accordance with CDRL A010 and CDRL Attachment 0001, a comprehensive SCRP that provides for identification and reporting of critical components associated with the secure supply of drug substance, drug product, and work-in-process through to finished goods, and key equipment suppliers and their locations, including addresses, points of contact, and work performed per location, to include subcontractors.

C.4.9 Risk Management Plan (RMP). The Contractor shall provide an RMP in accordance with CDRL A011 that outlines the impacts of each risk in relation to the cost, schedule, and performance objectives. The plan shall include risk mitigation strategies. Each risk mitigation strategy shall capture how the corrective action will reduce impacts on cost, schedule and performance.

C.4.10 Manufacturing Reports and Dose Tracking. The Contractor shall provide, in accordance with CDRL A013, manufacturing reports and manufacturing dose tracking projections and actuals utilizing the USG-provided “COVID-19 Dose Tracking Template” (CDRL Attachment 0003).

C.4.11 Product Acceptance Report (for each lot of Drug Product). The contractor shall provide, in accordance with CDRL A014, pictures of the drug product with lot number, drug product lot tree, list of associated deviations (from drug substance and product), and a Certificate of Analysis.

C.4.12 Incident Report. The contractor shall communicate to BARDA and document all critical programmatic concerns, issues, or probable risks that have or are likely to significantly impact project schedule and/or cost and/or performance in accordance with CDRL A016. “Significant” is frequently defined as a 10% or greater cost or schedule variance within a control account, but should be confirmed in consultation with the COR. Incidents that present liability to the project even without cost/schedule impact, such as breach of GCP during a clinical study, shall also be reported.

C.4.13 FDA Correspondence. The contractor shall provide any correspondence between Contractor and FDA relevant to the scope of this contract and submit in accordance with CDRL A017.

C.4.14 Press Releases. The contractor shall accurately and factually represent the work conducted under this contract in all press releases. The contractor shall provide an advance copy of any press release in accordance with CDRL A018.

C.5 Administration.

C.5.1 Post Award Teleconference. The contractor shall host a Post Award Teleconference within 7 calendar days after contract award.

C.5.1.1 The contractor shall provide an Agenda, IAW CDRL A020, detailing the planned activities for the subsequent 30 calendar days and shall discuss agenda items for the Post Award Kickoff Meeting.

C.5.1.2 The contractor shall provide Meeting Minutes IAW CDRL A021.

C.5.2 Post Award Kickoff Meeting. The contracting officer may request the contractor host a contract Kick-Off Meeting within 30 calendar days after contract award via teleconference. The contracting officer shall establish the date and time of the conference and prepare the agenda to include discussion on contract activities and schedule.

C.5.3 Bi-Weekly Teleconference. The contractor shall participate in bi-weekly teleconferences (or more frequent meetings required by the USG if warranted based on contract activities) to discuss performance on the contract.

C.5.4 The contractor shall provide an Agenda, IAW CDRL A020; Meeting Minutes in accordance with CDRL A021; and, Presentation Material in accordance with CDRL A022 for each of the aforementioned teleconferences or meetings throughout the contract period of performance.

C.5.5 Daily “Check-In”. The contractor shall participate in a daily “check-in” (via teleconference or email) to address key cost, schedule and technical updates. Daily updates may be shared with senior USG leaders during the COVID-19 response and should be provided on a non-confidential basis, unless the update includes confidential information in which case, the contractor shall provide the update in both confidential and non-confidential formats. Daily check-ins may occur on weekdays, excluding federal holidays. Upon request of the USG, check-ins may also occur on weekends and on federal holidays, provided at least 24 hours’ notice.

C.6 Security.

C.6.1 Access and General Protection/Security Policy and Procedures. The contractor shall provide all information required for background checks necessary to access critical information related to OWS, and to meet USG installation access requirements to be accomplished by the installation Director of Emergency Services or Security Office. The contractor employees shall comply with all personnel identity verification requirements as directed by the USG and/or local policy. In addition to the changes otherwise authorized by the changes clause of this contract, should the security status of OWS change the USG may require changes in the contractor’s security matters or processes. In addition to the industry standards for employment background checks, the contractor shall be willing to have key individuals, in exceptionally sensitive positions, identified for additional vetting by the United States USG.

C.6.2 Security Program and Plan. The contractor shall implement a comprehensive security program that provides overall protection of personnel, information, data, and facilities associated with fulfilling the USG’s requirement. The contractor’s security practices and procedures shall be detailed in a Security Plan, in accordance with CDRL A019, and shall demonstrate how the contractor shall meet and adhere to the security requirements outlined in CDRL Attachment 0002. This plan shall be delivered to the USG within 45 days of award, and the USG will review in detail and submit comments within ten (10) business days to the Contracting Officer (CO) to be forwarded to the Contractor. The Contractor shall review the Security Plan comments, and, submit a final Security Plan to the U.S. USG within thirty (30) calendar days after receipt of the comments. The Security Plan shall include a timeline for compliance of all the required security measures outlined in CDRL Attachment 0002.

C.6.3 Operational Security (OPSEC). The contractor shall develop and submit an OPSEC Standard Operating Procedure (SOP)/Plan IAW CDRL A024. The contractor shall identify in the SOP/Plan critical information related to this contract, why it needs to be protected, where it is located, who is responsible for it, and how to protect it.
C.7 **CLIN 0002 Vendor Managed Inventory (VMI).** The Contractor shall provide the capability to store the vaccine for up to 52 weeks, up to 100M doses of mRNA-1273 vaccine, in accordance with product labeling. The contractor shall, in accordance with paragraph C.3.1.1.6, ensure the product storage of FDP doses for up to 12 months prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations. The contractor shall store the product to insure product quality with audible alarms and contacting. The contractor shall notify the USG within of detection of an incident with the potential to impact product quality, and implement corrective actions to mitigate the incident. BARDA/JPEO-CBRND personnel may conduct Quality Audits of the storage facility, when deemed necessary. The contractor shall notify the USG of Corrective/Preventive actions within of detection of an incident with potential to impacts product quality. BARDA/JPEO-CBRND personnel may conduct Quality Audits of the storage facility, when deemed necessary.

C.7.1 The USG will provide the contractor advance notice of the required delivery locations for the vaccine. The contractor shall ship mRNA-1273 vaccines to designated locations in the United States. The contractor shall be responsible for shipment of all vaccine product whether acceptance is conducted at origin or destination.

C.7.2 The vaccine product shall be shipped and tracked by the distribution vendor’s shipping tracking number, to the USG-designated sites within the continental United States.

C.7.3 Implementation of a Vendor Managed Inventory Plan/SOP (CDRL A012) shall be provided to the USG. Notwithstanding either of the foregoing sentences, the contractor shall not be liable for loss of or damage to supplies caused by the negligence of officers, agents, or employees of the USG acting within the scope of their employment.
Section D - Packaging and Marking

D.1 Vaccine markings and labeling will be in accordance with FDA and will be finalized through a contract modification.
## INSPECTION AND ACCEPTANCE TERMS

Supplies/services will be inspected/accepted at:

<table>
<thead>
<tr>
<th>CLIN</th>
<th>INSPECT AT</th>
<th>INSPECT BY</th>
<th>ACCEPT AT</th>
<th>ACCEPT BY</th>
</tr>
</thead>
<tbody>
<tr>
<td>0001</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>0001AA</td>
<td>Origin</td>
<td>Government</td>
<td>Origin</td>
<td>Government</td>
</tr>
<tr>
<td>0001AB</td>
<td>Origin</td>
<td>Government</td>
<td>Origin</td>
<td>Government</td>
</tr>
<tr>
<td>0001AC</td>
<td>Destination</td>
<td>Government</td>
<td>Destination</td>
<td>Government</td>
</tr>
<tr>
<td>0001AD</td>
<td>Destination</td>
<td>Government</td>
<td>Destination</td>
<td>Government</td>
</tr>
<tr>
<td>0002</td>
<td>Destination</td>
<td>Government</td>
<td>Destination</td>
<td>Government</td>
</tr>
<tr>
<td>0003</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>0003AA</td>
<td>Destination</td>
<td>Government</td>
<td>Destination</td>
<td>Government</td>
</tr>
<tr>
<td>0003AB</td>
<td>Destination</td>
<td>Government</td>
<td>Destination</td>
<td>Government</td>
</tr>
<tr>
<td>0003AC</td>
<td>Destination</td>
<td>Government</td>
<td>Destination</td>
<td>Government</td>
</tr>
<tr>
<td>0003AD</td>
<td>Destination</td>
<td>Government</td>
<td>Destination</td>
<td>Government</td>
</tr>
<tr>
<td>0004</td>
<td>Destination</td>
<td>Government</td>
<td>Destination</td>
<td>Government</td>
</tr>
<tr>
<td>1001</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>1001AA</td>
<td>Destination</td>
<td>Government</td>
<td>Destination</td>
<td>Government</td>
</tr>
<tr>
<td>1001AB</td>
<td>Destination</td>
<td>Government</td>
<td>Destination</td>
<td>Government</td>
</tr>
<tr>
<td>1001AC</td>
<td>Destination</td>
<td>Government</td>
<td>Destination</td>
<td>Government</td>
</tr>
<tr>
<td>1002</td>
<td>Destination</td>
<td>Government</td>
<td>Destination</td>
<td>Government</td>
</tr>
<tr>
<td>2001</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>2001AA</td>
<td>Destination</td>
<td>Government</td>
<td>Destination</td>
<td>Government</td>
</tr>
<tr>
<td>2001AB</td>
<td>Destination</td>
<td>Government</td>
<td>Destination</td>
<td>Government</td>
</tr>
<tr>
<td>2001AC</td>
<td>Destination</td>
<td>Government</td>
<td>Destination</td>
<td>Government</td>
</tr>
<tr>
<td>2002</td>
<td>Destination</td>
<td>Government</td>
<td>Destination</td>
<td>Government</td>
</tr>
<tr>
<td>3001</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>3001AA</td>
<td>Destination</td>
<td>Government</td>
<td>Destination</td>
<td>Government</td>
</tr>
<tr>
<td>3001AB</td>
<td>Destination</td>
<td>Government</td>
<td>Destination</td>
<td>Government</td>
</tr>
<tr>
<td>3001AC</td>
<td>Destination</td>
<td>Government</td>
<td>Destination</td>
<td>Government</td>
</tr>
<tr>
<td>3002</td>
<td>Destination</td>
<td>Government</td>
<td>Destination</td>
<td>Government</td>
</tr>
<tr>
<td>4001</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>4001AA</td>
<td>Destination</td>
<td>Government</td>
<td>Destination</td>
<td>Government</td>
</tr>
<tr>
<td>4001AB</td>
<td>Destination</td>
<td>Government</td>
<td>Destination</td>
<td>Government</td>
</tr>
<tr>
<td>4001AC</td>
<td>Destination</td>
<td>Government</td>
<td>Destination</td>
<td>Government</td>
</tr>
<tr>
<td>4002</td>
<td>Destination</td>
<td>Government</td>
<td>Destination</td>
<td>Government</td>
</tr>
</tbody>
</table>

### CLAUSES INCORPORATED BY REFERENCE

52.246-16   Responsibility For Supplies   APR 1984

E1. Inspection:
Initial quality inspection of Filled Drug Product (FDP) shall occur when the Contractor performs release testing to confirm that products comply with Contractor's release specifications and criteria. Contractor will submit in WAWF to the Contracting Officer or the duly authorized representative of the Government with a Certificate of Analysis for quality inspection of all deliverables. Initial Inspection under this contract will be performed at the Contractor’s facility, or the subcontractor facility, by the BARDA Contracting Officer Technical Representative (COTR).

Final inspection of product shall occur when the Government inspects each shipment of product delivered to it hereunder for visible damage and quantity within [b (4)] of such delivery. In the event Contractor supplies any product to the Government and it is established that such Product was damaged or does not include the required quantities at the time of delivery, the Government shall promptly notify Contractor in writing within [b (4)]. Final inspection shall be conducted at the CDC location identified as destination.

In the event the USG requires storage of the FDP to a Vendor Managed Inventory (VMI) location, final quantity inspection shall be conducted by submission into WAWF of shipping or other documentation confirming quantity to VMI location. Final physical inspection of the FDP shall be conducted upon receipt of product to USG location.

Inspection of all reports and Contract Data Requirement List (CDRL) under this contract will be performed at Destination by duly authorized representative of the Government.

E.2 Acceptance

a. Acceptance at origin shall occur at [b (4)]. Acceptance at destination shall occur [b (4)]. Regardless of where acceptance occurs, the contractor is responsible for final delivery of Filled Drug Product (FDP) to a government designated CDC location.

b. Acceptance under this agreement will be performed by Army Contracting Command Aberdeen Proving Ground (ACC-APG) Natick Contracting Division (NCD) Contracting Officer.

c. Acceptance of services under VMI SubCLINS (List CLINS) shall occur upon satisfactory physical and quantity inspection of FDP upon delivery at USG designated CDC location.

d. The parties acknowledge that acceptance may depend on the compliance with the Contractor’s product specifications. The KO and COR may prior to acceptance consult with FDA under its authority under Public Law 115-92 to determine whether the material to be delivered meets the Contractor’s product specifications. To this end, Contractor agrees to provide a letter to FDA authorizing the Government to engage in dialog with FDA about the ultimate compliance of this product with the Contractor’s product specifications prior to acceptance. BARDA/COR will accept product according to the approved Product Acceptance Procedure.
# DELIVERY INFORMATION

<table>
<thead>
<tr>
<th>CLIN</th>
<th>DELIVERY DATE</th>
<th>QUANTITY</th>
<th>SHIP TO ADDRESS</th>
<th>DODAAC / CAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>(b) (4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- FOB: Origin (Shipping Point)
- FOB: Destination

N/A

N/A

FOB: Origin (Shipping Point)

N/A

FOB: Destination

N/A

FOB: Destination

N/A

FOB: Destination

N/A

FOB: Destination

(b) (4)

(b) (4)

(b) (4)

N/A

N/A

N/A

N/A

202-260-6798

DC 20024

N/A

N/A

FOB: Destination

N/A

FOB: Destination
<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>N/A</td>
</tr>
<tr>
<td>2</td>
<td>FOB: Destination</td>
</tr>
<tr>
<td>3</td>
<td>N/A</td>
</tr>
<tr>
<td>4</td>
<td>FOB: Destination</td>
</tr>
<tr>
<td>5</td>
<td>N/A</td>
</tr>
<tr>
<td>6</td>
<td>FOB: Destination</td>
</tr>
<tr>
<td>7</td>
<td>N/A</td>
</tr>
<tr>
<td>8</td>
<td>FOB: Destination</td>
</tr>
<tr>
<td>9</td>
<td>N/A</td>
</tr>
<tr>
<td>10</td>
<td>FOB: Destination</td>
</tr>
<tr>
<td>11</td>
<td>N/A</td>
</tr>
<tr>
<td>12</td>
<td>FOB: Destination</td>
</tr>
<tr>
<td>13</td>
<td>N/A</td>
</tr>
<tr>
<td>14</td>
<td>FOB: Destination</td>
</tr>
<tr>
<td>15</td>
<td>N/A</td>
</tr>
<tr>
<td>16</td>
<td>FOB: Destination</td>
</tr>
<tr>
<td>17</td>
<td>N/A</td>
</tr>
<tr>
<td>18</td>
<td>FOB: Destination</td>
</tr>
<tr>
<td>19</td>
<td>N/A</td>
</tr>
<tr>
<td>20</td>
<td>FOB: Destination</td>
</tr>
</tbody>
</table>

CLAUSES INCORPORATED BY REFERENCE
<table>
<thead>
<tr>
<th>Regulation</th>
<th>Description</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>52.211-17</td>
<td>Delivery of Excess Quantities</td>
<td>SEP 1989</td>
</tr>
<tr>
<td>52.242-15</td>
<td>Stop-Work Order</td>
<td>AUG 1989</td>
</tr>
<tr>
<td>52.247-34</td>
<td>F.O.B. Destination</td>
<td>NOV 1991</td>
</tr>
</tbody>
</table>

F.1 The contractor shall ship mRNA-1273 vaccines to designated locations in up to [D] (4) in the United States. The contractor shall be responsible for secure shipment of all vaccine product whether acceptance is conducted at origin or destination.
Section G - Contract Administration Data

ACCOUNTING AND APPROPRIATION DATA

<table>
<thead>
<tr>
<th>ACCOUNTING CODE</th>
<th>COST CODE</th>
<th>AMOUNT</th>
<th>CIN</th>
</tr>
</thead>
<tbody>
<tr>
<td>AA</td>
<td>0212020202120400000664643255</td>
<td>S.0074658.5.6</td>
<td>6100.9000021001</td>
</tr>
<tr>
<td></td>
<td>A5XAH</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>$955,500,000.00</td>
<td></td>
</tr>
<tr>
<td>AB</td>
<td>0212020202120400000664643255</td>
<td>S.0074658.5.6.1</td>
<td>6100.9000021001</td>
</tr>
<tr>
<td></td>
<td>A5XAH</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>$269,500,000.00</td>
<td></td>
</tr>
</tbody>
</table>

ACRN CLIN/SLIN CIN AMOUNT

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AA</td>
<td>0001AA</td>
<td>GFEB001153469300001</td>
<td>$183,750,000.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0001AC</td>
<td>GFEB001153469300003</td>
<td>$367,500,000.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0001AD</td>
<td>GFEB001153469300004</td>
<td>$404,250,000.00</td>
<td></td>
</tr>
<tr>
<td>AB</td>
<td>0001AB</td>
<td>GFEB001153469300002</td>
<td>$269,500,000.00</td>
<td></td>
</tr>
</tbody>
</table>

CLAUSES INCORPORATED BY REFERENCE

252.204-7006 Billing Instructions OCT 2005
252.232-7003 Electronic Submission of Payment Requests and Receiving Reports DEC 2018

CLAUSES INCORPORATED BY FULL TEXT

252.232-7006 WIDE AREA WORKFLOW PAYMENT INSTRUCTIONS (DEC 2018)

(a) Definitions. As used in this clause—

“Department of Defense Activity Address Code (DoDAAC)” is a six position code that uniquely identifies a unit, activity, or organization.

“Document type” means the type of payment request or receiving report available for creation in Wide Area Workflow (WAWF).

“Local processing office (LPO)” is the office responsible for payment certification when payment certification is done external to the entitlement system.

“Payment request” and “receiving report” are defined in the clause at 252.232-7003, Electronic Submission of Payment Requests and Receiving Reports.

(b) Electronic invoicing. The WAWF system provides the method to electronically process vendor payment requests and receiving reports, as authorized by Defense Federal Acquisition Regulation Supplement (DFARS) 252.232-7003, Electronic Submission of Payment Requests and Receiving Reports.

(c) WAWF access. To access WAWF, the Contractor shall—
(1) Have a designated electronic business point of contact in the System for Award Management at https://www.sam.gov; and

(2) Be registered to use WAWF at https://wawf.eb.mil/ following the step-by-step procedures for self-registration available at this web site.

(d) WAWF training. The Contractor should follow the training instructions of the WAWF Web-Based Training Course and use the Practice Training Site before submitting payment requests through WAWF. Both can be accessed by selecting the “Web Based Training” link on the WAWF home page at https://wawf.eb.mil/.

(e) WAWF methods of document submission. Document submissions may be via web entry, Electronic Data Interchange, or File Transfer Protocol.

(f) WAWF payment instructions. The Contractor shall use the following information when submitting payment requests and receiving reports in WAWF for this contract or task or delivery order:

(1) Document type. The Contractor shall submit payment requests using the following document type(s):

COMBO

(ii) For fixed price line items—

(A) That require shipment of a deliverable, submit the invoice and receiving report specified by the Contracting Officer.

Invoice and receiving report document type

(B) For services that do not require shipment of a deliverable, submit either the Invoice 2in1, which meets the requirements for the invoice and receiving report, or the applicable invoice and receiving report, as specified by the Contracting Officer.

N/A

(iii) For customary progress payments based on costs incurred, submit a progress payment request.

(iv) For performance based payments, submit a performance based payment request.

(v) For commercial item financing, submit a commercial item financing request.

(2) Fast Pay requests are only permitted when Federal Acquisition Regulation (FAR) 52.213-1 is included in the contract.

(3) Document routing. The Contractor shall use the information in the Routing Data Table below only to fill in applicable fields in WAWF when creating payment requests and receiving reports in the system.

Routing Data Table

<table>
<thead>
<tr>
<th>Field Name in WAWF</th>
<th>Data to be entered in WAWF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pay Official DoDAAC</td>
<td>HQ0337</td>
</tr>
<tr>
<td>Issue By DoDAAC</td>
<td>W911QY</td>
</tr>
<tr>
<td>Admin DoDAAC**</td>
<td>S2206A</td>
</tr>
</tbody>
</table>
(4) Payment request. The Contractor shall ensure a payment request includes documentation appropriate to the type of payment request in accordance with the payment clause, contract financing clause, or Federal Acquisition Regulation 52.216-7, Allowable Cost and Payment, as applicable.

(5) Receiving report. The Contractor shall ensure a receiving report meets the requirements of DFARS Appendix F.

(g) WAWF point of contact.

(1) The Contractor may obtain clarification regarding invoicing in WAWF from the following contracting activity’s WAWF point of contact.

(b) (6) / DCMA Boston-AFAW, Administrative Contracting Officer / (b) (6)

(2) Contact the WAWF helpdesk at (b) (6), if assistance is needed.

(End of clause)

FOR REFERENCE:

DFARS PGI 204.7108 Payment Instructions Table

https://www.acq.osd.mil/dpap/dars/pgi/pgi.htm/current/PGI204_71.htm#payment_instructions

G.1 GOVERNMENT CONTRACT ADMINISTRATION

In no event shall any understanding or agreement, contract modification, change order, or other matter in deviation from the terms of this contract between the Contractor and a person other than the Contracting Officer be effective or binding upon the Government. All such actions must be formalized by a proper contractual document executed by the Contracting Officer.

Procuring Contracting Officer:

(b) (6)

Bldg. 1, General Greene Avenue
Natick, MA 01760-5011

Contract Specialist:
G.2 GOVERNMENT TECHNICAL POINT OF CONTACT

Biologist/Project Officer
200 C Street, SW
Washington, DC 20201

G.3 CONTRACTOR'S CONTRACT ADMINISTRATION

ModernaTX, Inc.
200 Technology SQ.
Cambridge, MA 02139-3578

G.4 PLACES OF PERFORMANCE

ModernaTX, Inc.
200 Technology SQ.
Cambridge, MA 02139-3578

G.5 NOTIFICATION OF REVISIONS AND CHANGE

Notification of revision or changes to names or email addresses will be provided by official correspondence from the PCO/ACO or office of the PCO/ACO in lieu of a contract modification. This does not apply to any such revisions or changes in the event this contract includes a key personnel clause.

G.6 PERFORMANCE BASED PAYMENT

Performance-based payments (PBP) are authorized under this contract in accordance with FAR 52.232-32. The contractor shall bill for the PBP upon achievement of the completion criteria identified in Attachment 0008, Performance-based Payment Milestone Table. Upon achievement of the completion criteria, the contractor shall bill for the PBP for the base and each option IAW the following schedule:

<table>
<thead>
<tr>
<th>CLIN</th>
<th>PERIOD</th>
<th>AMOUNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>0001AA</td>
<td>BASE</td>
<td>$90,210,000</td>
</tr>
<tr>
<td>0001AA</td>
<td>BASE</td>
<td>$132,308,000</td>
</tr>
<tr>
<td>0001AA</td>
<td>BASE</td>
<td>$180,420,000</td>
</tr>
<tr>
<td>0001AA</td>
<td>BASE</td>
<td>$198,462,000</td>
</tr>
<tr>
<td>TOTAL</td>
<td></td>
<td>$601,400,000</td>
</tr>
</tbody>
</table>
Delivery Invoicing: PBPs are a type of contract financing and are recouped by the Government through deductions of payments otherwise due to the contractor for the partial or complete delivery of contract items. The deductions are made by applying a liquidation rate to the price of delivered contract items. Attachment 0009, Performance-based Payment Milestone Billing Plan, identifies the contractor invoicing schedule for liquidation. The contractor shall submit all invoices IAW Attachment 0009.
Section H - Special Contract Requirements

H.1 Key Personnel

Any key personnel specified in this contract are considered to be essential to work performance. At least thirty (30) calendar days prior to the Contractor voluntarily diverting any of the specified individuals to other programs or contracts the Contractor shall notify the Contracting Officer and shall submit a justification for the diversion or replacement and a request to replace the individual. The request must identify the proposed replacement and provide an explanation of how the replacement's skills, experience, and credentials meet or exceed the requirements of the contract (including, when applicable, Human Subjects Testing requirements). If the employee of the Contractor is terminated for cause or separates from the Contractor voluntarily with less than thirty (30) calendar-day notice, the Contractor shall provide the maximum notice practicable under the circumstances. The Contractor shall not divert, replace, or announce any such change to key personnel without the written consent of the Contracting Officer. The contract will be modified to add or delete key personnel as necessary to reflect the agreement of the parties. The following individuals are determined to be key personnel:

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>(b) (6)</td>
<td>Name Field</td>
</tr>
<tr>
<td></td>
<td>Name Field</td>
</tr>
<tr>
<td></td>
<td>Name Field</td>
</tr>
<tr>
<td></td>
<td>Name Field</td>
</tr>
</tbody>
</table>

H.2 Substitution of Key Personnel

The Contractor agrees to assign to the contract those persons whose resumes/CVs were submitted with the proposal who are necessary to fill the requirements of the contract. No substitutions shall be made except in accordance with this clause.

All requests for substitution must provide a detailed explanation of the circumstance necessitating the proposed substitution, a complete resume for the proposed substitute and any other information requested by the contracting officer to approve or disapprove the proposed substitution. All proposed substitutes must have qualifications that are equal to or higher than the qualifications of the person to be replaced. The contracting officer or authorized representative will evaluate such requests and promptly notify the contractor of his approval or disapproval thereof.

H.3 Disclosure of Information:

Performance under this contract may require the Contractor to access non-public data and information proprietary to a Government agency, another Government Contractor or of such nature that its dissemination or use other than as specified in the work statement would be adverse to the interests of the Government or others. Neither the Contractor, nor Contractor personnel, shall divulge nor release data nor information developed or obtained under performance of this contract, except authorized by Government personnel or upon written approval of the CO which the CO will provide in accordance with OWS or other Government policies and/or guidance. The Contractor shall not use, disclose, or reproduce proprietary data that bears a restrictive legend, other than as specified in this contract, or any information at all regarding this agency.

The Contractor shall comply with all applicable Government requirements for protection of non-public information. Unauthorized disclosure of nonpublic information is prohibited by the Government’s rules. Unauthorized disclosure may result in termination of the contract, replacement of a Contractor employee, or other appropriate redress. Neither the Contractor nor the Contractor’s employees shall disclose or cause to be disseminated, any information concerning the operations of the activity, which could result in, or increase the likelihood of, the possibility of a breach of the activity’s security or interrupt the continuity of its operations.
No information related to data obtained under this contract shall be released or publicized without the prior written consent of the COR, whose approval shall not be unreasonably withheld, conditioned, or delayed, provided that no such consent is required to comply with any law, rule, regulation, court ruling or similar order; for submission to any government entity for submission to any securities exchange on which the Contractor’s (or its parent corporation’s) securities may be listed for trading; or to third parties relating to securing, seeking, establishing or maintaining regulatory or other legal approvals or compliance, financing and capital raising activities, or mergers, acquisitions, or other business transactions. The exceptions identified in this paragraph apply to all disclosures under this Section H.3 except to the extent that a disclosure is otherwise prohibited by law.

H.4 Publication and Publicity

The contractor shall not release any reports, manuscripts, press releases, or abstracts about the work being performed under this contract without written notice in advance to the Government.

(a) Unless otherwise specified in this contract, the contractor may publish the results of its work under this contract. The contractor shall promptly send a copy of each submission to the COR for security review prior to submission. The contractor shall also inform the COR when the abstract article or other publication is published, and furnish a copy of it as finally published.

(b) Unless authorized in writing by the CO, the contractor shall not display the DoD logo including Operating Division or Staff Division logos on any publications.

(c) The contractor shall not reference the products(s) or services(s) awarded under this contract in commercial advertising, as defined in FAR 31.205-1, in any manner which states or implies DoD approval or endorsement of the product(s) or service(s) provided.

(d) The contractor shall include this clause, including this section (d) in all subcontracts where the subcontractor may propose publishing the results of its work under the subcontract. The contractor shall acknowledge the support of the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority whenever publicizing the work under this contract in any media by including an acknowledgement substantially as follows:

"This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract Number W911QY-20-C-0100."

H.5 Confidentiality of Information

a. Confidential information, as used in this article, means non-public information or data of a personal nature about an individual, or proprietary information or data submitted by or pertaining to an institution or organization.

b. The Contracting Officer and the Contractor may, by mutual consent, identify elsewhere in this contract specific information and/or categories of information which the Government will furnish to the Contractor or that the Contractor is expected to generate which is confidential. Similarly, the Contracting Officer and the Contractor may, by mutual consent, identify such confidential information from time to time during the performance of the contract. Failure to agree will be settled pursuant to the "Disputes" clause.

c. If it is established elsewhere in this contract that information to be utilized under this contract, or a portion thereof, is subject to the Privacy Act, the Contractor will follow the rules and procedures of disclosure set forth in the Privacy Act of 1974, 5 U.S.C. 552a, and implementing regulations and policies, with respect to systems of records determined to be subject to the Privacy Act.

d. Confidential information, as defined in paragraph (a) of this article, shall not be disclosed without the prior written consent of the individual, institution, or organization.
e. Whenever the Contractor is uncertain with regard to the proper handling of material under the contract, or if the material in question is subject to the Privacy Act or is confidential information subject to the provisions of this article, the Contractor shall obtain a written determination from the Contracting Officer prior to any release, disclosure, dissemination, or publication.

f. Contracting Officer Determinations will reflect the result of internal coordination with appropriate program and legal officials.

g. The provisions of paragraph (d) of this article shall not apply to conflicting or overlapping provisions in other Federal, State or local laws.

ALL REQUIREMENTS OF THIS SECTION H.5 MUST BE PASSED TO ALL SUB-CONTRACTOR.

H.6 Regulatory Rights

This contract involves supply of a product that requires FDA pre-market approval or clearance before commercial authorization. Contractor is seeking FDA authorization or clearance for the commercialization of mRNA-1273, Moderna vaccine for SARS-CoV-2 Coronavirus (the “Technology”). The Contractor is the Sponsor of the Regulatory Application (an investigational new drug application (IND), investigational device exemption (IDE), emergency use authorization (EUA), new drug application (NDA), biologics license application (BLA), premarket approval application (PMA), or 510(k) pre-market notification filing (510(k)) or another regulatory filing submitted to FDA) for the technology. As the Sponsor of the Regulatory Application to FDA (as the terms “sponsor” and “applicant” are defined or used in at 21 CFR §§3.2(c), 312.5, 600.3(t), 812.2(b), 812 Subpart C, or 814.20), the Contractor has certain standing before the FDA that entitles it to exclusive communications related to the Regulatory Application.

Accordingly, the Contractor and the Government agree to the following:

a. DoD Medical Product Priority. PL 115-92 allows the DoD to request, and FDA to provide, assistance to expedite development of products to diagnose, treat, or prevent serious or life-threatening diseases or conditions facing American military personnel. The contractor recognizes that only the DoD can utilize PL 115-92. As such, the contractor will work proactively with the Government to leverage this law to its maximum potential under this contract. The contractor shall submit Public Law 115-92 Sponsor Authorization Letter that will be delivered to the designated OWS POC(s) within 30 days of award.
Performance Based Payments (PBPs) have been authorized as a method of financing under this contract. In the event the Moderna’s mRNA-1273 COVID Vaccine is unsuccessful in its bid to obtain EUA or FDA approval, the Government may issue a Termination for Convenience (T4C) in whole or in part, on this contract. Upon notice of a T4C, the contractor shall submit a termination settlement proposal, IAW FAR 52.249-2, Termination for Convenience of the Government (Fixed-Price).

H.8 Public Readiness and Emergency Preparedness (PREP) Act:


(i) This Agreement is being entered into for purposes of facilitating the manufacture, testing, development, distribution, administration, and use of “Covered Countermeasures” for responding to the COVID-19 public health emergency, in accordance with Section VI of the PREP Act Declaration;

(ii) Contractor’s performance of this Agreement falls within the scope of the “Recommended Activities” for responding to the COVID-19 public health emergency, to the extent it is in accordance with Section III of the PREP Act Declaration; and

(iii) Contractor is a “Covered Person” to the extent it is a person defined in Section V of the PREP Act Declaration.

Therefore, in accordance with Sections IV and VII of the PREP Act Declaration as well as the PREP Act (42 U.S.C. § 247d-6d), the Department of Defense contracting via assisted acquisition on behalf of the HHS, expressly acknowledges and agrees that the HHS Declaration cited above, specifically its language providing immunity from suit and liability is applicable to this acquisition as long as Contractors activities fall within the terms and conditions of the PREP Act and the PREP Act Declaration.

The Government may not use, or authorize the use of, any products or materials provided under this contract, unless such use occurs in the United States (or a U.S. territory where U.S. law applies such as embassies, military and NATO installations) and is protected from liability under a declaration issued under the PREP Act, or a successor COVID-19 PREP Act Declaration of equal or greater scope. Any use where the application of the PREP Act is in question will be discussed with Moderna prior to use and, if the parties disagree on such use, the dispute will be resolved according to the “Disputes Clause” (52.233-1).

The items and technology covered by this Contract are being developed for both civil and military applications.
H.10  Ensuring Sufficient Supply of the Product

1. In recognition of the Government’s significant funding for the development and manufacturing of the product in this contract and the Government’s need to provide sufficient quantities of a COVID-19 vaccine to protect the United States population, the Government shall have the remedy described in this section to ensure sufficient supply of the product to meet the needs of the public health or national security. This remedy is not available to the Government unless and until both of the following conditions ((a) and (b)) are met:

   a. Moderna gives written notice, required to be submitted to the Government of:
      i. any formal management decision to terminate manufacturing of this product vaccine prior to delivery of any doses to USG under this contract, including all exercised options, other than as a result of clinical failure, or serious technical or safety reasons or;
      ii. any formal management decision to discontinue sale of this product vaccine to the Government prior to delivery of any doses to USG under this contract, including all exercised options, other than as a result of clinical failure, or serious technical or safety reasons; or
      iii. any filing that anticipates Federal bankruptcy protection; and
   b. Moderna has submitted an Emergency Use Authorization application under §564 of the FD&C Act or a biologics license application provisions of §351(a) of the Public Health Service Act (PHSA).

2. If both conditions listed in section 1 occur, Moderna, upon the request of the Government, shall provide the following items necessary for the Government to pursue manufacturing of this product vaccine with a third party for exclusive sale to the U.S. Government:

   a. a writing evidencing a non-exclusive, nontransferable, irrevocable (except for cause), royalty-free paid-up license to practice or have practiced for or on behalf of the U.S. Government any Moderna Background Patent, Copyright, other Moderna Intellectual Property, Moderna Know-How, Moderna Technical Data rights necessary to manufacture doses of the mRNA-1273 vaccine;
   b. necessary FDA regulatory filings or authorizations owned or controlled by Moderna related to this product vaccine and any confirmatory instrument pertaining thereto; and
   c. any outstanding Deliverables contemplated or materials purchased under this contract.

3. This remedy will remain available until the end of the contract.
H.12 Transportation to Final Destination

During the course of performance under this contract, the Government may require storage of the filled drug product (FDP) before delivery to the final government location. In these circumstances, the Government will accept FDP at the contractor facility (Origin). The contractor, however, shall continue to be responsible for secure delivery of the vaccine to its final destination as identified on this contract.

H.13 Validation of IP/Data

The Parties acknowledge that background intellectual property and technical data assertions have been made and evaluated by the parties. The parties agree that, should additional information relevant to these assertions become available, the parties will reevaluate said assertions as necessary in the future.

H.14 Novation

Upon Moderna, US, Inc.’s registration in the System for Award Management, the Government will, at the Contractor’s request, complete a novation of this Contract to recognize Moderna US, Inc. as a counterparty instead of Moderna TX, Inc. This novation will be completed through a modification executed by the Government that identifies Moderna US, Inc. as the contracting party for all purposes as if it had originally executed the Contract.
### Section 1 - Contract Clauses

#### CLAUSES INCORPORATED BY REFERENCE

<table>
<thead>
<tr>
<th>Clause Number</th>
<th>Description</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>52.202-1</td>
<td>Definitions</td>
<td>JUN 2020</td>
</tr>
<tr>
<td>52.202-3</td>
<td>Gratuities</td>
<td>APR 1984</td>
</tr>
<tr>
<td>52.202-5</td>
<td>Covenant Against Contingent Fees</td>
<td>MAY 2014</td>
</tr>
<tr>
<td>52.202-6</td>
<td>Restrictions On Subcontractor Sales To The Government</td>
<td>JUN 2020</td>
</tr>
<tr>
<td>52.203-7</td>
<td>Anti-Kickback Procedures</td>
<td>JUN 2020</td>
</tr>
<tr>
<td>52.203-8</td>
<td>Cancellation, Rescission, and Recovery of Funds for Illegal or Improper Activity</td>
<td>MAY 2014</td>
</tr>
<tr>
<td>52.203-10</td>
<td>Price Or Fee Adjustment For Illegal Or Improper Activity</td>
<td>MAY 2014</td>
</tr>
<tr>
<td>52.203-12</td>
<td>Limitation On Payments To Influence Certain Federal Transactions</td>
<td>JUN 2020</td>
</tr>
<tr>
<td>52.203-13</td>
<td>Contractor Code of Business Ethics and Conduct</td>
<td>JUN 2020</td>
</tr>
<tr>
<td>52.203-17</td>
<td>Contractor Employee Whistleblower Rights and Requirement To Inform Employees of Whistleblower Rights</td>
<td>JUN 2020</td>
</tr>
<tr>
<td>52.204-1</td>
<td>Approval of Contract</td>
<td>DEC 1989</td>
</tr>
<tr>
<td>52.204-4</td>
<td>Printed or Copied Double-Sided on Postconsumer Fiber Content Paper</td>
<td>MAY 2011</td>
</tr>
<tr>
<td>52.204-10</td>
<td>Reporting Executive Compensation and First-Tier Subcontract Awards</td>
<td>JUN 2020</td>
</tr>
<tr>
<td>52.204-13</td>
<td>System for Award Management Maintenance</td>
<td>OCT 2018</td>
</tr>
<tr>
<td>52.204-18</td>
<td>Commercial and Government Entity Code Maintenance</td>
<td>JUL 2016</td>
</tr>
<tr>
<td>52.204-19</td>
<td>Incorporation by Reference of Representations and Certifications.</td>
<td>DEC 2014</td>
</tr>
<tr>
<td>52.204-23</td>
<td>Prohibition on Contracting for Hardware, Software, and Services Developed or Provided by Kaspersky Lab and Other Covered Entities</td>
<td>JUL 2018</td>
</tr>
<tr>
<td>52.204-25</td>
<td>Prohibition on Contracting for Certain Telecommunications and Video Surveillance Services or Equipment</td>
<td>AUG 2019</td>
</tr>
<tr>
<td>52.209-6</td>
<td>Protecting the Government's Interest When Subcontracting With Contractors Debarred, Suspended, or Proposed for Debarment</td>
<td>JUN 2020</td>
</tr>
<tr>
<td>52.209-10</td>
<td>Prohibition on Contracting With Inverted Domestic Corporations</td>
<td>NOV 2015</td>
</tr>
<tr>
<td>52.210-1</td>
<td>Market Research</td>
<td>JUN 2020</td>
</tr>
<tr>
<td>52.215-2</td>
<td>Audit and Records--Negotiation</td>
<td>JUN 2020</td>
</tr>
<tr>
<td>52.215-8</td>
<td>Order of Precedence--Uniform Contract Format</td>
<td>OCT 1997</td>
</tr>
<tr>
<td>52.215-11</td>
<td>Price Reduction for Defective Certified Cost or Pricing Data-- Modifications</td>
<td>JUN 2020</td>
</tr>
<tr>
<td>52.215-13</td>
<td>Subcontractor Certified Cost or Pricing Data-- Modifications</td>
<td>JUN 2020</td>
</tr>
<tr>
<td>52.215-14</td>
<td>Integrity of Unit Prices</td>
<td>JUN 2020</td>
</tr>
<tr>
<td>52.215-15</td>
<td>Pension Adjustments and Asset Reversions</td>
<td>OCT 2010</td>
</tr>
<tr>
<td>52.215-18</td>
<td>Reversion or Adjustment of Plans for Postretirement Benefits (PRB) Other than Pensions</td>
<td>JUL 2005</td>
</tr>
<tr>
<td>52.215-19</td>
<td>Notification of Ownership Changes</td>
<td>OCT 1997</td>
</tr>
<tr>
<td>52.215-21</td>
<td>Requirements for Certified Cost or Pricing Data and Data Other Than Certified Cost or Pricing Data -- Modifications</td>
<td>JUN 2020</td>
</tr>
<tr>
<td>52.217-4</td>
<td>Evaluation Of Options Exercised At The Time Of Contract Award</td>
<td>JUN 1988</td>
</tr>
<tr>
<td>52.217-7</td>
<td>Option For Increased Quantity-Separately Priced Line Item</td>
<td>MAR 1989</td>
</tr>
<tr>
<td>52.217-8</td>
<td>Option To Extend Services</td>
<td>NOV 1999</td>
</tr>
<tr>
<td>52.219-8</td>
<td>Utilization of Small Business Concerns</td>
<td>OCT 2018</td>
</tr>
<tr>
<td>Section</td>
<td>Title</td>
<td>Date</td>
</tr>
<tr>
<td>------------------</td>
<td>----------------------------------------------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>52.219-28</td>
<td>Post-Award Small Business Program Rerepresentation</td>
<td>MAY 2020</td>
</tr>
<tr>
<td>52.221-1</td>
<td>Notice To The Government Of Labor Disputes</td>
<td>FEB 1997</td>
</tr>
<tr>
<td>52.222-3</td>
<td>Convict Labor</td>
<td>JUN 2003</td>
</tr>
<tr>
<td>52.222-19</td>
<td>Child Labor -- Cooperation with Authorities and Remedies</td>
<td>JAN 2020</td>
</tr>
<tr>
<td>52.222-21</td>
<td>Prohibition Of Segregated Facilities</td>
<td>APR 2015</td>
</tr>
<tr>
<td>52.222-26</td>
<td>Equal Opportunity</td>
<td>SEP 2016</td>
</tr>
<tr>
<td>52.222-35</td>
<td>Equal Opportunity for Veterans</td>
<td>JUN 2020</td>
</tr>
<tr>
<td>52.222-36</td>
<td>Equal Opportunity for Workers with Disabilities</td>
<td>JUN 2020</td>
</tr>
<tr>
<td>52.222-37</td>
<td>Employment Reports on Veterans</td>
<td>JUN 2020</td>
</tr>
<tr>
<td>52.222-40</td>
<td>Notification of Employee Rights Under the National Labor Relations Act</td>
<td>DEC 2010</td>
</tr>
<tr>
<td>52.222-50</td>
<td>Combating Trafficking in Persons</td>
<td>JAN 2019</td>
</tr>
<tr>
<td>52.222-54</td>
<td>Employment Eligibility Verification</td>
<td>OCT 2015</td>
</tr>
<tr>
<td>52.223-6</td>
<td>Drug-Free Workplace</td>
<td>MAY 2001</td>
</tr>
<tr>
<td>52.223-18</td>
<td>Encouraging Contractor Policies To Ban Text Messaging While Driving</td>
<td>JUN 2020</td>
</tr>
<tr>
<td>52.225-13</td>
<td>Restrictions on Certain Foreign Purchases</td>
<td>JUN 2008</td>
</tr>
<tr>
<td>52.227-1</td>
<td>Authorization and Consent</td>
<td>JUN 2020</td>
</tr>
<tr>
<td>52.227-1 Alt I</td>
<td>Authorization And Consent (JUN 2020) - Alternate I</td>
<td>APR 1984</td>
</tr>
<tr>
<td>52.227-2</td>
<td>Notice And Assistance Regarding Patent And Copyright Infringement</td>
<td>JUN 2020</td>
</tr>
<tr>
<td>52.227-11</td>
<td>Patent Rights--Ownership By The Contractor</td>
<td>MAY 2014</td>
</tr>
<tr>
<td>52.232-9</td>
<td>Limitation On Withholding Of Payments</td>
<td>APR 1984</td>
</tr>
<tr>
<td>52.232-17</td>
<td>Interest</td>
<td>MAY 2014</td>
</tr>
<tr>
<td>52.232-23</td>
<td>Assignment Of Claims</td>
<td>MAY 2014</td>
</tr>
<tr>
<td>52.232-25</td>
<td>Prompt Payment</td>
<td>JAN 2017</td>
</tr>
<tr>
<td>52.232-33</td>
<td>Payment by Electronic Funds Transfer--System for Award Management</td>
<td>OCT 2018</td>
</tr>
<tr>
<td>52.232-39</td>
<td>Unenforceability of Unauthorized Obligations</td>
<td>JUN 2013</td>
</tr>
<tr>
<td>52.232-40</td>
<td>Providing Accelerated Payments to Small Business Subcontractors</td>
<td>DEC 2013</td>
</tr>
<tr>
<td>52.233-1</td>
<td>Disputes</td>
<td>MAY 2014</td>
</tr>
<tr>
<td>52.233-3</td>
<td>Protest After Award</td>
<td>AUG 1996</td>
</tr>
<tr>
<td>52.233-4</td>
<td>Applicable Law for Breach of Contract Claim</td>
<td>OCT 2004</td>
</tr>
<tr>
<td>52.242-13</td>
<td>Bankruptcy</td>
<td>JUL 1995</td>
</tr>
<tr>
<td>52.243-1</td>
<td>Changes--Fixed Price</td>
<td>AUG 1987</td>
</tr>
<tr>
<td>52.243-7</td>
<td>Notification Of Changes</td>
<td>JAN 2017</td>
</tr>
<tr>
<td>52.244-5</td>
<td>Competition In Subcontracting</td>
<td>DEC 1996</td>
</tr>
<tr>
<td>52.245-9</td>
<td>Use And Charges</td>
<td>APR 2012</td>
</tr>
<tr>
<td>52.249-2</td>
<td>Termination For Convenience Of The Government (Fixed-Price)</td>
<td>APR 2012</td>
</tr>
<tr>
<td>52.249-8</td>
<td>Default (Fixed-Price Supply &amp; Service)</td>
<td>APR 1984</td>
</tr>
<tr>
<td>52.249-14</td>
<td>Excusable Delays</td>
<td>APR 1984</td>
</tr>
<tr>
<td>252.203-7000</td>
<td>Requirements Relating to Compensation of Former DoD Officials</td>
<td>SEP 2011</td>
</tr>
<tr>
<td>252.203-7002</td>
<td>Requirement to Inform Employees of Whistleblower Rights</td>
<td>SEP 2013</td>
</tr>
<tr>
<td>252.211-7003</td>
<td>Item Unique Identification and Valuation</td>
<td>MAR 2016</td>
</tr>
<tr>
<td>252.222-7006</td>
<td>Restrictions on the Use of Mandatory Arbitration Agreements</td>
<td>DEC 2010</td>
</tr>
<tr>
<td>252.225-7048</td>
<td>Export-Controlled Items</td>
<td>JUN 2013</td>
</tr>
<tr>
<td>252.227-7013</td>
<td>Rights in Technical Data--Noncommercial Items</td>
<td>FEB 2014</td>
</tr>
<tr>
<td>252.227-7016</td>
<td>Rights in Bid or Proposal Information</td>
<td>JAN 2011</td>
</tr>
</tbody>
</table>
CLAUSES INCORPORATED BY FULL TEXT

52.217-9  OPTION TO EXTEND THE TERM OF THE CONTRACT (MAR 2000)

(a) The Government may extend the term of this contract by written notice to the Contractor within 5 days for;
provided that the Government gives the Contractor a preliminary written notice of its intent to extend at least 30
days for Options 1 and 2, 60 days for Option 3 and 4 before the contract expires. The preliminary notice does not
commit the Government to an extension.

(b) If the Government exercises this option, the extended contract shall be considered to include this option clause.

(c) The total duration of this contract, including the exercise of any options under this clause, shall not exceed 20
months.

(End of clause)

52.232-32  PERFORMANCE-BASED PAYMENTS (APR 2012)

(a) Amount of payments and limitations on payments. Subject to such other limitations and conditions as are
specified in this contract and this clause, the amount of payments and limitations on payments shall be specified in
the contract's description of the basis for payment.

(b) Contractor request for performance-based payment. The Contractor may submit requests for payment of
performance-based payments not more frequently than monthly, in a form and manner acceptable to the Contracting
Officer. Unless otherwise authorized by the Contracting Officer, all performance-based payments in any period for
which payment is being requested shall be included in a single request, appropriately itemized and totaled. The
Contractor's request shall contain the information and certification detailed in paragraphs (1) and (m) of this clause.

(c) Approval and payment of requests.

(1) The Contractor shall not be entitled to payment of a request for performance-based payment prior to successful
accomplishment of the event or performance criterion for which payment is requested. The Contracting Officer shall
determine whether the event or performance criterion for which payment is requested has been successfully
accomplished in accordance with the terms of the contract. The Contracting Officer may, at any time, require the
Contractor to substantiate the successful performance of any event or performance criterion which has been or is
represented as being payable.

(2) A payment under this performance-based payment clause is a contract financing payment under the Prompt
Payment clause of this contract and not subject to the interest penalty provisions of the Prompt Payment Act. The
designated payment office will pay approved requests on the 30th day after receipt of the request for performance-
based payment by the designated payment office. However, the designated payment office is not required to provide
payment if the Contracting Officer requires substantiation as provided in paragraph (c)(1) of this clause, or inquiries into the status of an event or performance criterion, or into any of the conditions listed in paragraph (e) of this clause, or into the Contractor certification. The payment period will not begin until the Contracting Officer approves the request.

(3) The approval by the Contracting Officer of a request for performance-based payment does not constitute an acceptance by the Government and does not excuse the Contractor from performance of obligations under this contract.

(d) Liquidation of performance-based payments.

(1) Performance-based finance amounts paid prior to payment for delivery of an item shall be liquidated by deducting a percentage or a designated dollar amount from the delivery payment. If the performance-based finance payments are on a delivery item basis, the liquidation amount for each such line item shall be the percent of that delivery item price that was previously paid under performance-based finance payments or the designated dollar amount. If the performance-based finance payments are on a whole contract basis, liquidation shall be by either predesignated liquidation amounts or a liquidation percentage.

(2) If at any time the amount of payments under this contract exceeds any limitation in this contract, the Contractor shall repay to the Government the excess. Unless otherwise determined by the Contracting Officer, such excess shall be credited as a reduction in the unliquidated performance-based payment balance(s), after adjustment of invoice payments and balances for any retroactive price adjustments.

(e) Reduction or suspension of performance-based payments. The Contracting Officer may reduce or suspend performance-based payments, liquidate performance-based payments by deduction from any payment under the contract, or take a combination of these actions after finding upon substantial evidence any of the following conditions:

(1) The Contractor failed to comply with any material requirement of this contract (which includes paragraphs (h) and (i) of this clause).

(2) Performance of this contract is endangered by the Contractor's --

(i) Failure to make progress; or

(ii) Unsatisfactory financial condition.

(3) The Contractor is delinquent in payment of any subcontractor or supplier under this contract in the ordinary course of business.

(f) Title.

(1) Title to the property described in this paragraph (f) shall vest in the Government. Vestiture shall be immediately upon the date of the first performance-based payment under this contract, for property acquired or produced before that date. Otherwise, vestiture shall occur when the property is or should have been allocable or properly chargeable to this contract.

(2) "Property," as used in this clause, includes all of the following described items acquired or produced by the Contractor that are or should be allocable or properly chargeable to this contract under sound and generally accepted accounting principles and practices:

(i) Parts, materials, inventories, and work in process;

(ii) Special tooling and special test equipment to which the Government is to acquire title;
(iii) Nondurable (i.e., noncapital) tools, jigs, dies, fixtures, molds, patterns, taps, gauges, test equipment and other similar manufacturing aids, title to which would not be obtained as special tooling under subparagraph (f)(2)(ii) of this clause; and

(iv) Drawings and technical data, to the extent the Contractor or subcontractors are required to deliver them to the Government by other clauses of this contract.

(3) Although title to property is in the Government under this clause, other applicable clauses of this contract (e.g., the termination or clauses) shall determine the handling and disposition of the property.

(4) The Contractor may sell any scrap resulting from production under this contract, without requesting the Contracting Officer's approval, provided that any significant reduction in the value of the property to which the Government has title under this clause is reported in writing to the Contracting Officer.

(5) In order to acquire for its own use or dispose of property to which title is vested in the Government under this clause, the Contractor shall obtain the Contracting Officer's advance approval of the action and the terms. If approved, the basis for payment (the events or performance criteria) to which the property is related shall be deemed to be not in compliance with the terms of the contract and not payable (if the property is part of or needed for performance), and the Contractor shall refund the related performance-based payments in accordance with paragraph (d) of this clause.

(6) When the Contractor completes all of the obligations under this contract, including liquidation of all performance-based payments, title shall vest in the Contractor for all property (or the proceeds thereof) not --

(i) Delivered to, and accepted by, the Government under this contract; or

(ii) Incorporated in supplies delivered to, and accepted by, the Government under this contract and to which title is vested in the Government under this clause.

(7) The terms of this contract concerning liability for Government-furnished property shall not apply to property to which the Government acquired title solely under this clause.

(g) Risk of loss. Before delivery to and acceptance by the Government, the Contractor shall bear the risk of loss for property, the title to which vests in the Government under this clause, except to the extent the Government expressly assumes the risk. If any property is lost (see 45.101), the basis of payment (the events or performance criteria) to which the property is related shall be deemed to be not in compliance with the terms of the contract and not payable (if the property is part of or needed for performance), and the Contractor shall refund the related performance-based payments in accordance with paragraph (d) of this clause.

(h) Records and controls. The Contractor shall maintain records and controls adequate for administration of this clause. The Contractor shall have no entitlement to performance-based payments during any time the Contractor's records or controls are determined by the Contracting Officer to be inadequate for administration of this clause.

(i) Reports and Government access. The Contractor shall promptly furnish reports, certificates, financial statements, and other pertinent information requested by the Contracting Officer for the administration of this clause and to determine that an event or other criterion prompting a financing payment has been successfully accomplished. The Contractor shall give the Government reasonable opportunity to examine and verify the Contractor's records and to examine and verify the Contractor's performance of this contract for administration of this clause.

(j) Special terms regarding default. If this contract is terminated under the Default clause,

(1) the Contractor shall, on demand, repay to the Government the amount of unliquidated performance-based payments, and

(2) title shall vest in the Contractor, on full liquidation of all performance-based payments, for all property for which
the Government elects not to require delivery under the Default clause of this contract. The Government shall be liable for no payment except as provided by the Default clause.

(k) Reservation of rights.

(1) No payment or vesting of title under this clause shall --

(i) Excuse the Contractor from performance of obligations under this contract; or

(ii) Constitute a waiver of any of the rights or remedies of the parties under the contract.

(2) The Government's rights and remedies under this clause --

(i) Shall not be exclusive, but rather shall be in addition to any other rights and remedies provided by law or this contract; and

(ii) Shall not be affected by delayed, partial, or omitted exercise of any right, remedy, power, or privilege, nor shall such exercise or any single exercise preclude or impair any further exercise under this clause or the exercise of any other right, power, or privilege of the Government.

(l) Content of Contractor's request for performance-based payment. The Contractor's request for performance-based payment shall contain the following:

(1) The name and address of the Contractor;

(2) The date of the request for performance-based payment;

(3) The contract number and/or other identifier of the contract or order under which the request is made;

(4) Such information and documentation as is required by the contract's description of the basis for payment; and

(5) A certification by a Contractor official authorized to bind the Contractor, as specified in paragraph (m) of this clause.

(m) Content of Contractor's certification. As required in paragraph (l)(5) of this clause, the Contractor shall make the following certification in each request for performance-based payment:

I certify to the best of my knowledge and belief that --

(1) This request for performance-based payment is true and correct; this request (and attachments) has been prepared from the books and records of the Contractor, in accordance with the contract and the instructions of the Contracting Officer;

(2) (Except as reported in writing on _________), all payments to subcontractors and suppliers under this contract have been paid, or will be paid, currently, when due in the ordinary course of business;

(3) There are no encumbrances (except as reported in writing on _________) against the property acquired or produced for, and allocated or properly chargeable to, the contract which would affect or impair the Government's title;

(4) There has been no materially adverse change in the financial condition of the Contractor since the submission by the Contractor to the Government of the most recent written information dated _________; and

(5) After the making of this requested performance-based payment, the amount of all payments for each deliverable item for which performance-based payments have been requested will not exceed any limitation in the contract, and
the amount of all payments under the contract will not exceed any limitation in the contract.

(End of Clause)

52.252-2 CLAUSES INCORPORATED BY REFERENCE (FEB 1998)

This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at this/these address(es):

https://www.acquisition.gov/content/regulations

(End of clause)

52.252-6 AUTHORIZED DEVIATIONS IN CLAUSES (APR 1984)

(a) The use in this solicitation or contract of any Federal Acquisition Regulation (48 CFR Chapter 1) clause with an authorized deviation is indicated by the addition of "(DEVIATION)" after the date of the clause.

(b) The use in this solicitation or contract of any Defense Federal Acquisition Regulation Supplement (48 CFR Chapter 2) clause with an authorized deviation is indicated by the addition of "(DEVIATION)" after the name of the regulation.

(End of clause)
### List of Documents, Exhibits and Other Attachments

<table>
<thead>
<tr>
<th>Document Type</th>
<th>Description</th>
<th>Page #</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exhibit A</td>
<td>CDRLs</td>
<td>14</td>
<td>18 July 2020</td>
</tr>
<tr>
<td>Attachment 0001</td>
<td>Supply Chain Resiliency Plan for CDRL A010</td>
<td>2</td>
<td>23 July 2020</td>
</tr>
<tr>
<td>Attachment 0002</td>
<td>Security Plan</td>
<td>6</td>
<td>23 July 2020</td>
</tr>
<tr>
<td>Attachment 0003</td>
<td>Dose Tracking Template Draft Moderna Excel</td>
<td></td>
<td>15 July 2020</td>
</tr>
<tr>
<td>Attachment 0004</td>
<td>Data Rights</td>
<td>1</td>
<td>7 August 2020</td>
</tr>
<tr>
<td>Attachment 0005</td>
<td>[b] (4)</td>
<td></td>
<td>7 August 2020</td>
</tr>
<tr>
<td>Attachment 0006</td>
<td>ModernaTx, Inc. Background Intellectual Property</td>
<td>2</td>
<td>6 August 2020</td>
</tr>
<tr>
<td>Attachment 0007</td>
<td>Performance Base Payment Milestone Schedule</td>
<td>1</td>
<td>7 August 2020</td>
</tr>
<tr>
<td>Attachment 0008</td>
<td>Performance Base Payment Milestone Billing Plan</td>
<td>15</td>
<td>7 August 2020</td>
</tr>
</tbody>
</table>

### Exhibit A

**Contract Data Requirements List (CDRL)**

<table>
<thead>
<tr>
<th>Data Item #</th>
<th>Title of Data Item</th>
<th>Subtitle</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>A001</td>
<td>Quality Audit Finding and Response Record (QAFRR)</td>
<td>BARDA Audit Findings Report</td>
<td>18-Jul-20</td>
</tr>
<tr>
<td>A002</td>
<td>Quality Audit Finding and Response Record (QAFRR)</td>
<td>FDA Audit Findings Report</td>
<td>18-Jul-20</td>
</tr>
<tr>
<td>A003</td>
<td>Contractor Furnished Material (CFM) Report</td>
<td>Monthly Inventory Report</td>
<td>18-Jul-20</td>
</tr>
<tr>
<td>A004</td>
<td>Quality Program Plan</td>
<td>Quality Program Plan</td>
<td>18-Jul-20</td>
</tr>
<tr>
<td>A005</td>
<td>Task Directive Documentation</td>
<td>Shipping Documentation - Finished Drag Products (FDP)</td>
<td>18-Jul-20</td>
</tr>
<tr>
<td>A006</td>
<td>Task Directive Documentation</td>
<td>Expiring Item Report</td>
<td>18-Jul-20</td>
</tr>
<tr>
<td>A007</td>
<td>Contractor’s Personnel Roster</td>
<td>Key Personnel Listing</td>
<td>18-Jul-20</td>
</tr>
<tr>
<td>A008</td>
<td>Status Report</td>
<td>Monthly Technical Progress Report</td>
<td>18-Jul-20</td>
</tr>
<tr>
<td>A010</td>
<td>Supply Chain Risk Management Plan</td>
<td>Supply Chain Resiliency Plan (SCRP)</td>
<td>18-Jul-20</td>
</tr>
<tr>
<td>A011</td>
<td>Contractor’s Risk Management Plan</td>
<td>Risk Management Plan (RMP)</td>
<td>18-Jul-20</td>
</tr>
<tr>
<td>A012</td>
<td>Research and Development of Medical Products Regulated by the U.S. Food and Drug Administration</td>
<td>Vendor Managed Inventory Plan/SOP</td>
<td>18 Jul 20</td>
</tr>
<tr>
<td>A013</td>
<td>Internal Contractor Technical Data</td>
<td>Manufacturing Reports and Dose Tracking Projections/Actuals</td>
<td>18-Jul-20</td>
</tr>
<tr>
<td>A014</td>
<td>Certificate of Compliance (Analysis)</td>
<td>Product Acceptance Report</td>
<td>18-Jul-20</td>
</tr>
<tr>
<td>A015</td>
<td>N/A</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>A016</td>
<td>Accident Incident Report</td>
<td>Incident Report</td>
<td>18-Jul-20</td>
</tr>
<tr>
<td>A017</td>
<td>Internal Contractor Technical Data Report</td>
<td>FDA Correspondence</td>
<td>18-Jul-20</td>
</tr>
<tr>
<td>A018</td>
<td>Acquisition Support Documentation</td>
<td>Press Releases</td>
<td>18-Jul-20</td>
</tr>
<tr>
<td>A019</td>
<td>Contractor’s Standard Operating Procedures</td>
<td>Security Plan</td>
<td>18-Jul-20</td>
</tr>
<tr>
<td>A020</td>
<td>Conference Agenda</td>
<td>Conference Agenda</td>
<td>18-Jul-20</td>
</tr>
<tr>
<td>A021</td>
<td>Report, Record of Meeting/Minutes</td>
<td>Meeting Minutes</td>
<td>18-Jul-20</td>
</tr>
<tr>
<td>A022</td>
<td>Presentation Material</td>
<td>Presentation Material</td>
<td>18-Jul-20</td>
</tr>
<tr>
<td>A023</td>
<td>N/A</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>A024</td>
<td>Operations Security (OPSEC) Plan</td>
<td>Operational Security (OPSEC) SOP/Plan</td>
<td>18 Jul 20</td>
</tr>
<tr>
<td>A025</td>
<td>Research and Development of Medical Products Regulated by the U.S. Food &amp; Drug Administration (FDA)</td>
<td>Manufacturing Development Plan</td>
<td>18 Jul 20</td>
</tr>
</tbody>
</table>
## AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT

### 2 AMENDMENT/MODIFICATION NO.
- **P00004**

### 3 EFFECTIVE DATE
- **11-Feb-2021**

### 4 REQUISITION/PURCHASE REQ NO.
- **SEE SCHEDULE**

### 6 ISSUED BY
- **W911QV**

### 7 ADMINISTERED BY (Other than item 6)
- **DEFENSE CONTRACT MANAGEMENT AGENCY**
- **DCMA BOSTON**
- **465 SUMMER STREET**
- **BOSTON MA 02110-2138**

### 8 NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code)
- **MODERNUS US, NC.**
- **9 Technology St**
- **CAMBRIDGE MA 02139-3578**

### 9A. AMENDMENT OF SOLICITATION NO.
- **W011QY**

### 9B. DATED (SEE ITEM 11)
- **09-Aug-2020**

### 10A. MOD. OF CONTRACT/ORDER NO.
- **W011QY 2201004**

### 10B. DATED (SEE ITEM 13)
- **08-Aug-2020**

### 11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS
- The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer is extended, is not extended.

### 12. ACCOUNTING AND APPROPRIATION DATA (If required)
- **SEE SCHEDULE**

### 13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACT/ORDERS.

### A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (*Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. AS DESCRIBED IN ITEM 10A.

### B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).

### C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
- **See Block 14 Continuation Page**

### D. OTHER (Specify type of modification and authority)
- **See Block 14 Continuation Page**

### 14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)
- **Modification Control Number:** 211178
- **See Block 14 Continuation Page**

**Exempt as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.**

### 15A. NAME AND TITLE OF SIGNER (Type or print)
- **(b) (6)**

### 15B. CONTRACTOR/OFFICER
- **(b) (6)**

### 15C. DATE SIGNED
- **11-Feb-2021**

### 16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)
- **Contracting Officer**

### 16B. UNITED STATES OF AMERICA
- **(b) (6)**

### 16C. DATE SIGNED
- **11-Feb-2021**
SUMMARY OF CHANGES

The following have been added by full text:

OBLIGATION AMOUNT: \( \text{b) (4)} \)

a. The purpose of this modification (P00004) is to:
   - Exercise, fund Option 2 CLINs 2001AA, 2001AB, 2001AC for a total of \( \text{b) (4)} \) (Authority FAR 52.217-7)
   - Add clauses H.16 & H.17, and revise the delivery schedule for the Base period, Option 1, and Option 2 IAW the table contained within H.16 (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties)
   - Revise the table in Section G back to previous amounts, due to an administrative error on modification no. P00003, where the amounts were revised (Authority FAR 52.232-16)
   - Update Contract Data Requirement List (CDRL) no.'s A003, A008, A009, A011, A014, A021, and the corresponding information to the CDRLs in Section C, Statement of Work. (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties)

b. This modification was requested by the program office to meet the Government’s mission requirements.

c. The total contract value and total funded amount has increased by \( \text{b) (4)} \) from \( \text{b) (4)} \) to \( \text{b) (4)} \).

All other terms and conditions remain unchanged. Please see below for details.

SECTION A - SOLICITATION/CONTRACT FORM

The total cost of this contract was increased by \( \text{b) (4)} \) from \( \text{b) (4)} \) to \( \text{b) (4)} \).

SECTION B - SUPPLIES OR SERVICES AND PRICES

CLIN 0001
The CLIN extended description has changed from:

The contractor shall produce and deliver \( \text{b) (4)} \) of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP), IAW Section C, Statement of Work (SOW) and CDRLs (Exhibit A) on this contract.

To:
The contractor shall produce and deliver of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP) IAW clause H.16 Delivery Schedule, Section C Statement of Work (SOW), and CDRLs (Exhibit A) on this contract.

CLIN 1001
The CLIN extended description has changed from:

The contractor shall produce and deliver of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP), IAW Section C, Statement of Work (SOW) and CDRLs (Exhibit A) on this contract.

To:

The contractor shall produce and deliver of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP) IAW clause H.16 Delivery Schedule, Section C Statement of Work (SOW), and CDRLs (Exhibit A) on this contract.

CLIN 2001
The CLIN extended description has changed from:

The contractor shall produce and deliver of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP), IAW Section C, Statement of Work (SOW) and CDRLs (Exhibit A) on this contract.

To:

The contractor shall produce and deliver of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP) IAW clause H.16 Delivery Schedule, Section C Statement of Work (SOW), and CDRLs (Exhibit A) on this contract.

The option status has changed from Option to Option Exercised.

SUBCLIN 2001AA
The option status has changed from Option to Option Exercised.

SUBCLIN 2001AB
The option status has changed from Option to Option Exercised.

SUBCLIN 2001AC
The option status has changed from Option to Option Exercised.
SECTION C - DESCRIPTIONS AND SPECIFICATIONS

The following have been modified:

**STATEMENT OF WORK**

**LARGE SCALE PRODUCTION OF SARS-CoV-2 VACCINE**

C.1 **SCOPE.** The Department of Defense and Health and Human Services (HHS) require large scale manufacturing of vaccine doses in support of the national emergency response to the Coronavirus Disease 2019 (COVID-19) for the United States Government (USG) and the US population.

C.1.1 **Background.** In December 2019, a novel coronavirus now known as SARS-CoV-2 was first detected in Wuhan, Hubei Province, People’s Republic of China, causing outbreaks of the coronavirus disease COVID-19 that has now spread globally. The Secretary of Health and Human Service declared a public health emergency on January 31, 2020, under section 319 of the Public Health Service Act (42 U.S.C. 247d), in response to COVID-19. On March 1, 2020, the President of the United States, pursuant to sections 01 and 301 of the National Emergencies Act (50 U.S.C. 1601 et seq.) and consistent with section 1135 of the Social Security Act (SSA), as amended (42 U.S.C. 1320b-5), proclaimed that the COVID-19 outbreak in the United States constitutes a national emergency.

C.1.1.1 Under Operation Warp Speed (OWS), the Department of Defense and HHS are leading a whole of nation effort to ensure development of promising vaccine, diagnostic and therapeutic candidates and ensure that these medical countermeasures are available in the quantities required to reduce SARS-CoV-2 transmission, identify prior and/or current infection, and improve patient care, thereby mitigating the impact of COVID-19 on the nation and its people. The DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRD) is providing expertise and contracting support to HHS, in compliance with PL 115-92 Authorization Letter for DoD Medical Priorities, through an Interagency Agreement, signed April 23, 2020. As OWS products progress to clinical trials to evaluate the safety and efficacy of vaccines and therapeutics, it is critical that, in parallel, the USG supports large scale manufacturing so that vaccine doses or therapeutic treatment courses are immediately available for nationwide access as soon as a positive efficacy signal is obtained and the medical countermeasures are authorized for widespread use.

C.1.2 **Objective:** The objective of this effort is to obtain the following:

   a. Base Period: Large scale manufacturing of 100 million vaccine doses
   b. Option Period 1: Large scale manufacturing of 100 million vaccine doses
   c. Option Period 2: Large scale manufacturing of 100 million vaccine doses
   d. Option Period 3: Large scale manufacturing of 100 million vaccine doses
   e. Option Period 4: Large scale manufacturing of 100 million vaccine doses

The Base Period is 9 months, with overlapping options for a total of 20 months if all options are exercised.

C.2 **APPLICABLE DOCUMENTS.**

C.2.1 Federal Documents:

C.2.1.1 Title 21 Code of Federal Regulations (CFR), Food and Drugs: Part 210, Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General; and, Part 211, Current Good Manufacturing Practice In Manufacturing, Processing, Packing, or Holding of Drugs; General. (https://www.ecfr.gov/cgi-bin/textidx?SID=a95cab20f443897a400bb7e44a27cf4c&mc=true&tpl=/ecfrbrowse/Title21/21cfrv4_02.tpl#0)

C.3 **REQUIREMENTS.** Independently, and not as an agent of the USG, in accordance with the Proposal submitted by Moderna US, Inc. in response to Solicitation Number W911QY20R0043, Titled, “Advanced
Procurement of mRNA-1273 Vaccine for Prevention of SARS-CoV-2 Coronavirus (COVID-19"), dated July 10, 2020 (and any subsequent USG-approved revisions thereto), the contractor shall provide all necessary services, qualified personnel, material, equipment and facilities (not otherwise provided by the USG under the terms of this contract) to perform the specific tasks set forth below.

C.3.1 **Contract Line Item Number (CLIN) 0001 - Base Period: Large Scale Manufacturing of 100 Million Vaccine Doses.**

C.3.1.1 The contractor shall complete all scope required for the production, release and delivery use of 100 million Final Drug Product (FDP) doses of a SARS-CoV-2 mRNA-1273 vaccine. This shall include, the following tasks and other activities reasonably contemplated by such task:

C.3.1.1.1 Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations. Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of 12 months. (Based on FDP stability data that supports a 12-month shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC. Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.

C.3.1.1.2 cGMP manufacturing of 100 million doses fully compliant with 21 CFR 210 and 211.

C.3.1.1.3 Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated as appropriate.

C.3.1.1.4 Coordinating with FDA to establish an approved commercial vial label, carton and packaging insert (printed or electronic).

C.3.1.1.5 Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements, subject to any exceptions established by or the enforcement discretion of the FDA, including "Exemption from Certain Product Tracing and Product Identification Requirements Under Section 582 of the FD&C Act" (April 2020).

C.3.1.1.6 In coordination with the USG, the contractor shall conduct a demonstration of the vaccine shipping process prior to the first delivery of FDP doses at a time mutually agreed to by the contractor and the USG. Moderna shall provide specifications and details associated with the shipping process and containers (I A W CDRL A005) to enable the USG to adequately plan and prepare for potential distribution of the vaccine.

C.3.1.1.7 Following release of product the contractor shall, promptly deliver product to the designated delivery site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below. In the unforeseen event that a designated delivery site cannot receive product and the contractor provides storage beyond 20 days of product release, the contract will be subject to modification for acceptance purposes.

C.3.1.2 Site Visits and Audits. The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.

C.3.1.2.1 BARDA Audits. If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.

C.3.1.2.2 FDA Audits. The Contractor shall notify the Contracting Officer and Contracting Officer’s Representative (COR) within [D] (4) of a scheduled FDA audit or within [D] (4) of an ad hoc site visit or audit if the FDA does not provide advance notice. The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [D] (4) of.
receiving correspondence from the FDA or third party in accordance with CDRL A002. The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within of submittal of the audit report in accordance with CDRL A002.

C.3.1.2.3 FDA Interactions. The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologics for the following, but not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.

C.3.2 CLIN 1001 - Option Period 1: Large Scale Manufacturing of 100 Million Vaccine Doses.

C.3.2.1 The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine. This shall include the following tasks and other activities reasonably contemplated by such tasks:

C.3.2.1.1 Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations. Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of 12 months. (Based on FDP stability data that supports a 12-month shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207. Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC. Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.

C.3.2.1.2 cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.

C.3.2.1.3 Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated.

C.3.2.1.4 Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA.

C.3.2.1.5 Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below. To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site’s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site.

C.3.2.2 Site Visits and Audits. The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.

C.3.2.2.1 BARDA Audits. If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.

C.3.2.2.2 FDA Audits. The Contractor shall notify the Contracting Officer and COR within (b) (4) of a scheduled FDA audit or within (b) (4) of an ad hoc site visit or audit if the FDA does not provide advance notice. The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within (b) (4) of receiving correspondence from the FDA or third party in accordance with CDRL A015. The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within (b) (4) of submittal of the audit report in accordance with CDRL A002.
C.3.2.2.3 FDA Interactions. The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologics for the following, but not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.

C.3.3 **CLIN 2001 - Option Period 2: Large Scale Manufacturing of 100 Million Vaccine Doses.**

C.3.3.1 The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine. This shall include the following tasks and other activities reasonably contemplated by such tasks:

C.3.3.1.1 Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations. Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of 12 months. (Based on FDP stability data that supports a 12-month shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC. Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.

C.3.3.1.2 cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.

C.3.3.1.3 Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated as appropriate.

C.3.3.1.4 Ensuring that the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements, subject to any exceptions established by or the enforcement discretion of the FDA.

C.3.3.1.5 Following release the contractor shall deliver product to the nearest designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below. To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site’s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site.

C.3.3.2 Site Visits and Audits. The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.

C.3.3.2.1 BARDA Audits. If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.

C.3.3.2.2 FDA Audits. The Contractor shall notify the Contracting Officer and COR within [b] (4) [c] of a scheduled FDA audit or within [b] (4) [c] of an ad hoc site visit or audit if the FDA does not provide advance notice. The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [b] (4) [c] of receiving correspondence from the FDA or third party in accordance with CDRL A002. The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within [b] (4) [c] of submittal of the audit report in accordance with CDRL A002.

C.3.3.2.3 FDA Interactions. The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologics for the following, but not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.
C.3.4 **CLIN 3001 - Option Period 3: Large Scale Manufacturing of 100 Million Vaccine Doses.**

C.3.4.1 The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine. This shall include the following tasks and other activities reasonably contemplated by such tasks:

C.3.4.1.1 Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations. Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of 12 months. (Based on FDP stability data that supports a 12-month shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC. Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.

C.3.4.1.2 cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.

C.3.4.1.3 Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated.

C.3.4.1.4 Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA.

C.3.4.1.5 Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below. To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site’s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site.

C.3.4.2 Site Visits and Audits. The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.

C.3.4.2.1 BARDA Audits. If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.

C.3.4.2.2 FDA Audits. The Contractor shall notify the Contracting Officer and COR within (b) (4) of a scheduled FDA audit or within (b) (4) of an ad hoc site visit or audit if the FDA does not provide advance notice. The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within (b) (4) of receiving correspondence from the FDA or third party in accordance with CDRL A015. The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within (b) (4) of submittal of the audit report in accordance with CDRL A002.

C.3.4.2.3 FDA Interactions. The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding mRNA-1273 for the following, but not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.

C.3.5 **CLIN 4001 - Option Period 4: Large Scale Manufacturing of 100 Million Vaccine Doses.**

C.3.5.1 The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine. This shall include the following tasks and other activities reasonably contemplated by such tasks:
C.3.5.1.1 Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations. Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of 12 months. (Based on FDP stability data that supports a 12-month shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC. Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.

C.3.5.1.2 cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.

C.3.5.1.3 Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated.

C.3.5.1.4 Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA.

C.3.5.1.5 Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below. To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site's ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site.

C.3.5.2 Site Visits and Audits. The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.

C.3.5.2.1 BARDA Audits. If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.

C.3.5.2.2 FDA Audits. The Contractor shall notify the Contracting Officer and COR within (b) (4) of a scheduled FDA audit or within (b) (4) of an ad hoc site visit or audit if the FDA does not provide advance notice. The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within (b) (4) of receiving correspondence from the FDA or third party in accordance with CDRL A015. The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within (b) (4) of submittal of the audit report in accordance with CDRL A002.

C.3.5.2.3 FDA Interactions. The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologics for the following, but not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.

C.4 CLIN 0002: Data Deliverables. The contractor shall provide the following in accordance with the Contract Data Requirements List (CDRL), DD Forms 1423, provided at Appendix A.

C.4.1 Monthly Inventory Report (CDRL A003), detailing at a minimum, raw materials, Bulk-mRNA, formulated LNPs, and the fill, finish, and released product.

C.4.2 Quality Management Plan. The contractor shall provide a Quality Management Plan, in accordance with CDRL A004, describing the quality policy and objectives, management review, competencies and training, process document control, feedback, evaluation, corrective action and preventive action, process improvement, measurement, and data analysis processes. The framework is normally divided into infrastructure, senior
management responsibility, resource management, lifecycle management, and quality management system.

C.4.3 Shipping Documentation (CDRL A005) for all Finished Drug Product (FDP) transferring from the contractor’s fill/finish facility to a USG facility. The contractor shall obtain concurrence on planned shipment protocols prior to transport.

C.4.4 Expiring Items Report (CDRL A006) for all FDP in the USG’s possession.

C.4.5 Key Personnel Listing (CDRL A007).

C.4.6 Monthly Technical Progress Report (CDRL A008), to include an Integrated Master Schedule, identifying key activities and contract status.

C.4.7 Final Technical Report (CDRL A009), documenting the work performed and results obtained for the entire contract period of performance.

C.4.8 Supply Chain Resiliency Plan (SCRP). The contractor shall provide, in accordance with CDRL A010 and CDRL Attachment 0001, a comprehensive SCRP that provides for identification and reporting of critical components associated with the secure supply of drug substance, drug product, and work-in-process through to finished goods, and key equipment suppliers and their locations, including addresses, points of contact, and work performed per location, to include subcontractors.

C.4.9 Risk Management Plan (RMP). The Contractor shall provide an RMP in accordance with CDRL A011 that outlines the impacts of each risk in relation to the cost, schedule, and performance objectives. The plan shall include risk mitigation strategies. Each risk mitigation strategy shall capture how the corrective action will reduce impacts on cost, schedule and performance. The following RMP information shall be included in the Monthly Technical Progress Report (CDRL A008).

Risk Register content:
- a. Manuf/FF -risks or possible delays. If none N/A
- b. Supply chain – same as above
- c. Distribution challenges – same as above
- d. Regulatory – same as above

C.4.10 Manufacturing Reports and Dose Tracking. The Contractor shall provide, in accordance with CDRL A013, manufacturing reports and manufacturing dose tracking projections and actuals utilizing the USG-provided “COVID-19 Dose Tracking Template” (CDRL Attachment 0003).

C.4.11 Product Acceptance Report (for each lot of Drug Product). The contractor shall provide, in accordance with CDRL A014, pictures of the drug product with lot number, drug product lot tree, list of associated deviations (from drug substance and product), and a Certificate of Analysis.

C.4.12 Incident Report. The contractor shall communicate to BARDA and document all critical programmatic concerns, issues, or probable risks that have or are likely to significantly impact project schedule and/or cost and/or performance in accordance with CDRL A016. “Significant” is frequently defined as a 10% or greater cost or schedule variance within a control account, but should be confirmed in consultation with the COR. Incidents that present liability to the project even without cost/schedule impact, such as breach of GCP during a clinical study, shall also be reported.

C.4.13 FDA Correspondence. The contractor shall provide any correspondence between Contractor and FDA relevant to the scope of this contract and submit in accordance with CDRL A017.
C.4.14 Press Releases. The contractor shall accurately and factually represent the work conducted under this contract in all press releases. The contractor shall provide an advance copy of any press release in accordance with CDRL A018.


C.5 Administration.

C.5.1 Post Award Teleconference. The contractor shall host a Post Award Teleconference within 15 calendar days after contract award.

C.5.1.1 The contractor shall provide an Agenda, IAW CDRL A020, detailing the planned activities for the subsequent 30 calendar days and shall discuss agenda items for the Post Award Kickoff Meeting.

C.5.1.2 The contractor shall provide Meeting Minutes IAW CDRL A021.

C.5.2 Post Award Kickoff Meeting. The contracting officer may request the contractor host a contract Kick-Off Meeting within 30 calendar days after contract award via teleconference. The contracting officer shall establish the date and time of the conference and prepare the agenda to include discussion on contract activities and schedule.

C.5.3 Bi-Weekly Teleconference. The contractor shall participate in bi-weekly teleconferences (or more frequent meetings required by the USG if warranted based on contract activities) to discuss performance on the contract.

C.5.4 The contractor shall provide an Agenda, IAW CDRL A020; Meeting Minutes in accordance with CDRL A021; and, Presentation Material in accordance with CDRL A022 for each of the aforementioned teleconferences or meetings throughout the contract period of performance.

C.5.5 Daily “Check-In”. The contractor shall participate in a daily “check-in” (via teleconference or email) to address key cost, schedule and technical updates. Daily updates may be shared with senior USG leaders during the COVID-19 response and should be provided on a non-confidential basis, unless the update includes confidential information in which case, the contractor shall provide the update in both confidential and non-confidential formats. Daily check-ins may occur on weekdays, excluding federal holidays. Upon request of the USG, check-ins may also occur on weekends and on federal holidays, provided at least 24 hours’ notice.

C.6 Security.

C.6.1 Access and General Protection/Security Policy and Procedures. The contractor shall provide all information required for background checks necessary to access critical information related to OWS, and to meet USG installation access requirements to be accomplished by the installation Director of Emergency Services or Security Office. The contractor employees shall comply with all personnel identity verification requirements as directed by the USG and/or local policy. In addition to the changes otherwise authorized by the changes clause of this contract, should the security status of OWS change the USG may require changes in the contractor’s security matters or processes. In addition to the industry standards for employment background checks, the contractor shall be willing to have key individuals, in exceptionally sensitive positions, identified for additional vetting by the United States USG.

C.6.2 Security Program and Plan. The contractor shall implement a comprehensive security program that provides overall protection of personnel, information, data, and facilities associated with fulfilling the USG’s requirement. The contractor’s security practices and procedures shall be detailed in a Security Plan, in accordance with CDRL A019, and shall demonstrate how the contractor shall meet and adhere to the security requirements outlined in CDRL Attachment 0002. This plan shall be delivered to the USG within 45 days of award, and the USG will review in detail and submit comments within ten (10) business days to the Contracting Officer (CO) to be forwarded to the
Contractor. The Contractor shall review the Security Plan comments, and, submit a final Security Plan to the U.S. USG within thirty (30) calendar days after receipt of the comments. The Security Plan shall include a timeline for compliance of all the required security measures outlined in CDRL Attachment 0002.

C.6.3 Operational Security (OPSEC). The contractor shall develop and submit an OPSEC Standard Operating Procedure (SOP)/Plan IAW CDRL A024. The contractor shall identify in the SOP/Plan critical information related to this contract, why it needs to be protected, where it is located, who is responsible for it, and how to protect it.

C.7 CLIN 0002 Vendor Managed Inventory (VMI). The Contractor shall provide the capability to store the vaccine for up to 52 weeks, up to 100M doses of mRNA-1273 vaccine, in accordance with product labeling. The contractor shall, in accordance with paragraph C.3.1.1.6, ensure the product storage of FDP doses for up to 12 months prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations. Risk of loss of or damage to supplies shall remain with the contractor until delivery of Filled Drug Product (FDP) to a government facility. The contractor shall store the product to insure product quality with audible alarms and contacting. The contractor shall notify the USG within [b] (4) of detection of an incident with the potential to impact product quality, and implement corrective actions to mitigate the incident. BARDA/JPEO-CBRND personnel may conduct Quality Audits of the storage facility, when deemed necessary. The contractor shall notify the USG of Corrective/Preventive actions within [b] (4) of detection of an incident with potential to impacts product quality. BARDA/JPEO-CBRND personnel may conduct Quality Audits of the storage facility, when deemed necessary.

C.7.1 The USG will provide the contractor advance notice of the required delivery locations for the vaccine. The contractor shall ship mRNA-1273 vaccines to designated locations [b] (4) in the United States. The contractor shall be responsible for shipment of all vaccine product whether acceptance is conducted at origin or destination. Regardless of where acceptance occurs, risk of loss of or damage to supplies shall remain with the contractor until delivery of Filled Drug Product (FDP) to a government facility.

C.7.2 The vaccine product shall be shipped and tracked by the distribution vendor’s shipping tracking number, to the USG-designated sites within the continental United States.

C.7.3 The contractor shall retain physical risk of loss for all product stored as VMI until subsequent delivery to and acceptance by the USG at the USG-designated site. Implementation of a Vendor Managed Inventory Plan/SOP (CDRL A012) shall be provided to the USG. If the drug product is initially delivered to a USG site instead of VMI, risk of loss will transfer upon delivery and acceptance at the USG-designated site. Notwithstanding either of the foregoing sentences, the contractor shall not be liable for loss of or damage to supplies caused by the negligence of officers, agents, or employees of the USG acting within the scope of their employment.

SECTION E - INSPECTION AND ACCEPTANCE

The following have been modified:

E1. Inspection:

Vaccine CLINs:
Quality inspection of Filled Drug Product (FDP) shall occur when the Contractor performs release testing to confirm that products complies with Contractor’s release specifications and criteria. Contractor will submit the Certificate of Analysis for quality inspection of all drug product lots in BARDA Data Infrastructure (BDI) system. Initial
The Government shall inspect each shipment of product delivered to it hereunder for visible damage and quantity. In the event Contractor supplies any product to the Government and it is established that such Product was damaged or does not include the required quantities at the time of final delivery, the Government shall promptly notify Contractor in writing. A BDI extract of the inspection documentation shall also be submitted in Wide Area Workflow (WAWF) as supporting documentation for invoice submittals.

Storage CLIN:
In the event the USG requires storage of the FDP to a Vendor Managed Inventory (VMI) location, quantity inspection shall be conducted by submission of shipping or other documentation into WAWF confirming quantity to VMI location. Physical inspection of the FDP shall be conducted upon receipt of product to USG CDC location.

Data CLIN:
Inspection of all reports and Contract Data Requirement List (CDRL) under this contract will be performed at Destination by duly authorized representative of the Government.

E.2 Acceptance

a. Acceptance at origin shall occur at the contractor or subcontractor facility. Acceptance at destination shall occur at a government designated CDC location. Regardless of where acceptance occurs, the contractor is responsible for final delivery of Filled Drug Product (FDP) to a government designated CDC location.

b. Acceptance of vaccines under this agreement will be performed by the COTR in the BDI system, which constitutes government acceptance at origin. Documentation of acceptance shall be submitted in accordance with WAWF instructions.

c. Acceptance of storage services under VMI CLIN No. 0002 shall occur upon satisfactory physical and quantity inspection of FDP upon delivery at USG designated CDC location. Acceptance of Data CLIN No. 0004 shall occur in WAWF by the KO.

d. The parties acknowledge that acceptance may depend on the compliance with the Contractor’s product specifications. The KO and COR may prior to acceptance consult with FDA under its authority under Public Law 115-92 to determine whether the material to be delivered meets the Contractor’s product specifications. To this end, Contractor agrees to provide a letter to FDA authorizing the Government to engage in dialog with FDA about the ultimate compliance of this product with the Contractor’s product specifications prior to acceptance. BARDA/COR will accept product according to the approved Product Acceptance Procedure.

SECTION F - DELIVERIES OR PERFORMANCE

The following Delivery Schedule item for SUBCLIN 1001AB has been changed from:

<table>
<thead>
<tr>
<th>DELIVERY DATE</th>
<th>QUANTITY</th>
<th>SHIP TO ADDRESS</th>
<th>DODAAC / CAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The following Delivery Schedule item for SUBCLIN 1001AC has been changed from:

<table>
<thead>
<tr>
<th>DELIVERY DATE</th>
<th>QUANTITY</th>
<th>SHIP TO ADDRESS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The following Delivery Schedule item for SUBCLIN 2001AA has been changed from:

<table>
<thead>
<tr>
<th>DELIVERY DATE</th>
<th>QUANTITY</th>
<th>SHIP TO ADDRESS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The following Delivery Schedule item for SUBCLIN 2001AA has been changed from:

<table>
<thead>
<tr>
<th>DELIVERY DATE</th>
<th>QUANTITY</th>
<th>SHIP TO ADDRESS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The following Delivery Schedule item for SUBCLIN 2001AB has been changed from:

<table>
<thead>
<tr>
<th>DELIVERY DATE</th>
<th>QUANTITY</th>
<th>SHIP TO ADDRESS</th>
<th>DODAAC / CAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>(b) (4)</td>
<td>(b) (4)</td>
<td></td>
<td>W56XNH</td>
</tr>
</tbody>
</table>

The following Delivery Schedule item for SUBCLIN 2001AC has been changed from:

<table>
<thead>
<tr>
<th>DELIVERY DATE</th>
<th>QUANTITY</th>
<th>SHIP TO ADDRESS</th>
<th>DODAAC / CAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>(b) (4)</td>
<td>(b) (4)</td>
<td></td>
<td>W56XNH</td>
</tr>
</tbody>
</table>
The following have been modified:

F.1 The contractor shall ship mRNA-1273 vaccines to the designated locations listed below. The contractor shall be responsible for secure shipment of all vaccine product whether acceptance is conducted at origin or destination.

Delivery Locations:
SECTION G - CONTRACT ADMINISTRATION DATA

Accounting and Appropriation

Summary for the Payment Office

As a result of this modification, the total funded amount for this document was increased by [b] (4) [e].

SUBCLIN 2001AA:

AF: 021202120400000665654255 S.0074658.5,44 6100.9000021001 A5XAH (CIN GFEBS001160755900001) was increased by [b] (4) [e] from [b] (4) [e] to [b] (4) [e].

The contract ACRN AF has been added.
The CIN GFEBS001160755900001 has been added.
The Cost Code [b] (4) [e] has been added.

SUBCLIN 2001AB:

AG: 021202120400000665654255 S.0074658.5,44,2 6100.9000021001 A5XAH (CIN GFEBS001160755900002) was increased by [b] (4) [e] from [b] (4) [e] to [b] (4) [e].

The contract ACRN AG has been added.
The CIN GFEBS001160755900002 has been added.
The Cost Code [b] (4) [e] has been added.

SUBCLIN 2001AC:

AH: 021202120400000665654255 S.0074658.5,44,3 6100.9000021001 A5XAH (CIN GFEBS001160755900003) was increased by [b] (4) [e] from [b] (4) [e] to [b] (4) [e].

The contract ACRN AH has been added.
The CIN GFEBS001160755900003 has been added.
The Cost Code [b] (4) [e] has been added.

The following have been modified:

G.1 GOVERNMENT CONTRACT ADMINISTRATION

In no event shall any understanding or agreement, contract modification, change order, or other matter in deviation from the terms of this contract between the Contractor and a person other than the Contracting Officer be effective or binding upon the Government. All such actions must be formalized by a proper contractual document executed by the Contracting Officer.

Procuring Contracting Officer: [b] (6) [e]

Bldg. 1, General Greene Avenue
Natick, MA 01760-5011
G.2 GOVERNMENT TECHNICAL POINT OF CONTACT

(b) (6)
Biologist/Project Officer
200 C Street, SW
Washington, DC 20201

G.3 CONTRACTOR’S CONTRACT ADMINISTRATION

(b) (6)
Moderna US, Inc.
200 Technology SQ.
Cambridge, MA 02139-3578

G.4 PLACES OF PERFORMANCE

Moderna US, Inc.
200 Technology SQ.
Cambridge, MA 02139-3578

G.5 NOTIFICATION OF REVISIONS AND CHANGE

Notification of revision or changes to names or email addresses will be provided by official correspondence from the PCO/ACO or office of the PCO/ACO in lieu of a contract modification. This does not apply to any such revisions or changes in the event this contract includes a key personnel clause.

G.6 PERFORMANCE BASED PAYMENT

Performance-based payments (PBP) are authorized under this contract in accordance with FAR 52.232-32. The contractor shall bill for the PBP upon achievement of the completion criteria identified in Attachment 0007, Performance-based Payment Milestone Table. Upon achievement of the completion criteria, the contractor shall bill for the PBP for the base and each option IAW the following schedule:

(b) (4)
Delivery Invoicing: PBPs are a type of contract financing and are recouped by the Government through deductions of payments otherwise due to the contractor for the partial or complete delivery of contract items. The deductions are made by applying a liquidation rate to the price of delivered contract items. Attachment 0008, Performance-based Payment Milestone Billing Plan, identifies the contractor invoicing schedule for liquidation. The contractor shall submit all invoices IAW Attachment 0008 dated 4 December 2020.

252.232-7006 WIDE AREA WORKFLOW PAYMENT INSTRUCTIONS (DEC 2018)

(a) Definitions. As used in this clause—

“Department of Defense Activity Address Code (DoDAAC)” is a six position code that uniquely identifies a unit, activity, or organization.

“Document type” means the type of payment request or receiving report available for creation in Wide Area Workflow (WAWF).

“Local processing office (LPO)” is the office responsible for payment certification when payment certification is done external to the entitlement system.

“Payment request” and “receiving report” are defined in the clause at 252.232-7003, Electronic Submission of Payment Requests and Receiving Reports.

(b) Electronic invoicing. The WAWF system provides the method to electronically process vendor payment requests and receiving reports, as authorized by Defense Federal Acquisition Regulation Supplement (DFARS) 252.232-7003, Electronic Submission of Payment Requests and Receiving Reports.

(c) WAWF access. To access WAWF, the Contractor shall—

(1) Have a designated electronic business point of contact in the System for Award Management at https://www.sam.gov; and

(2) Be registered to use WAWF at https://wawf.eb.mil/ following the step-by-step procedures for self-registration available at this web site.

(d) WAWF training. The Contractor should follow the training instructions of the WAWF Web-Based Training Course and use the Practice Training Site before submitting payment requests through WAWF. Both can be accessed by selecting the “Web Based Training” link on the WAWF home page at https://wawf.eb.mil/.

(e) WAWF methods of document submission. Document submissions may be via web entry, Electronic Data Interchange, or File Transfer Protocol.

(f) WAWF payment instructions. The Contractor shall use the following information when submitting payment requests and receiving reports in WAWF for this contract or task or delivery order:

(1) Document type. The Contractor shall submit payment requests using the following document type(s):

COMBO
(ii) For fixed price line items—

(A) That require shipment of a deliverable, submit the invoice and receiving report specified by the Contracting Officer.

Invoice and receiving report document type

(B) For services that do not require shipment of a deliverable, submit either the Invoice 2in1, which meets the requirements for the invoice and receiving report, or the applicable invoice and receiving report, as specified by the Contracting Officer.

N/A

(iii) For customary progress payments based on costs incurred, submit a progress payment request.

(iv) For performance based payments, submit a performance based payment request.

(v) For commercial item financing, submit a commercial item financing request.

(2) Fast Pay requests are only permitted when Federal Acquisition Regulation (FAR) 52.213-1 is included in the contract.

(3) Document routing. The Contractor shall use the information in the Routing Data Table below only to fill in applicable fields in WAWF when creating payment requests and receiving reports in the system.

Routing Data Table

<table>
<thead>
<tr>
<th>Field Name in WAWF</th>
<th>Data to be entered in WAWF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pay Official DoDAAC</td>
<td>HQ0337</td>
</tr>
<tr>
<td>Issue By DoDAAC</td>
<td>W911QY</td>
</tr>
<tr>
<td>Admin DoDAAC</td>
<td>S2206A</td>
</tr>
<tr>
<td>Inspect By DoDAAC</td>
<td>W56XNH</td>
</tr>
<tr>
<td>Acceptor</td>
<td>W911QY</td>
</tr>
<tr>
<td>Ship To</td>
<td>TDB</td>
</tr>
</tbody>
</table>

(4) Payment request. The Contractor shall ensure a payment request includes documentation appropriate to the type of payment request in accordance with the payment clause, contract financing clause, or Federal Acquisition Regulation 52.216-7, Allowable Cost and Payment, as applicable.

(5) Receiving report. The Contractor shall ensure a receiving report meets the requirements of DFARS Appendix F.

(g) WAWF point of contact.

(1) The Contractor may obtain clarification regarding invoicing in WAWF from the following contracting activity’s WAWF point of contact.

(b) (6) / DCMA Boston-AFAW, Administrative Contracting Officer (b) (6)
(2) Contact the WAWF helpdesk at 866-618-5988, if assistance is needed.

(End of clause)

FOR REFERENCE:

DFARS PGI 204.7108 Payment Instructions Table

https://www.acq.osd.mil/dpap/dars/pgi/pgi.htm/current/PGI204_71.htm#payment_instructions

SECTION H - SPECIAL CONTRACT REQUIREMENTS

The following have been modified:

H.1 Key Personnel

Any key personnel specified in this contract are considered to be essential to work performance. At least thirty (30) calendar days prior to the Contractor voluntarily diverting any of the specified individuals to other programs or contracts the Contractor shall notify the Contracting Officer and shall submit a justification for the diversion or replacement and a request to replace the individual. The request must identify the proposed replacement and provide an explanation of how the replacement's skills, experience, and credentials meet or exceed the requirements of the contract (including, when applicable, Human Subjects Testing requirements). If the employee of the Contractor is terminated for cause or separates from the Contractor voluntarily with less than thirty (30) calendar-day notice, the Contractor shall provide the maximum notice practicable under the circumstances. The Contractor shall not divert, replace, or announce any such change to key personnel without the written consent of the Contracting Officer. The contract will be modified to add or delete key personnel as necessary to reflect the agreement of the parties. The following individuals are determined to be key personnel:

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>(D) (6)</td>
<td></td>
</tr>
</tbody>
</table>

H.2 Substitution of Key Personnel
The Contractor agrees to assign to the contract those persons whose resumes/CVs were submitted with the proposal who are necessary to fill the requirements of the contract. No substitutions shall be made except in accordance with this clause.

All requests for substitution must provide a detailed explanation of the circumstance necessitating the proposed substitution, a complete resume for the proposed substitute and any other information requested by the contracting officer to approve or disapprove the proposed substitution. All proposed substitutes must have qualifications that are equal to or higher than the qualifications of the person to be replaced. The contracting officer or authorized representative will evaluate such requests and promptly notify the contractor of his approval or disapproval thereof.

H.3 Disclosure of Information:

Performance under this contract may require the Contractor to access non-public data and information proprietary to a Government agency, another Government Contractor or of such nature that its dissemination or use other than as specified in the work statement would be adverse to the interests of the Government or others. Neither the Contractor, nor Contractor personnel, shall divulge nor release data nor information developed or obtained under performance of this contract, except authorized by Government personnel or upon written approval of the CO which the KO will provide in accordance with OWS or other Government policies and/or guidance. The Contractor shall not use, disclose, or reproduce proprietary data that bears a restrictive legend, other than as specified in this contract, or any information at all regarding this agency.

The Contractor shall comply with all applicable Government requirements for protection of non-public information. Unauthorized disclosure of nonpublic information is prohibited by the Government’s rules. Unauthorized disclosure may result in termination of the contract, replacement of a Contractor employee, or other appropriate redress. Neither the Contractor nor the Contractor’s employees shall disclose or cause to be disseminated, any information concerning the operations of the activity, which could result in, or increase the likelihood of, the possibility of a breach of the activity’s security or interrupt the continuity of its operations.

No information related to data obtained under this contract shall be released or publicized without the prior written consent of the COR, whose approval shall not be unreasonably withheld, conditioned, or delayed, provided that no such consent is required to comply with any law, rule, regulation, court ruling or similar order; for submission to any government entity for submission to any securities exchange on which the Contractor’s (or its parent corporation’s) securities may be listed for trading; or to third parties relating to securing, seeking, establishing or maintaining regulatory or other legal approvals or compliance, financing and capital raising activities, or mergers, acquisitions, or other business transactions. The exceptions identified in this paragraph apply to all disclosures under this Section H.3 except to the extent that a disclosure is otherwise prohibited by law.

H.4 Publication and Publicity

The contractor shall not release any reports, manuscripts, press releases, or abstracts about the work being performed under this contract without written notice in advance to the Government.

(a) Unless otherwise specified in this contract, the contractor may publish the results of its work under this contract. The contractor shall promptly send a copy of each submission to the COR for security review prior to submission. The contractor shall also inform the COR when the abstract article or other publication is published, and furnish a copy of it as finally published.

(b) Unless authorized in writing by the CO, the contractor shall not display the DoD logo including Operating Division or Staff Division logos on any publications.

(c) The contractor shall not reference the products(s) or services(s) awarded under this contract in commercial advertising, as defined in FAR 31.205-1, in any manner which states or implies DoD approval or endorsement of the product(s) or service(s) provided.
(d) The contractor shall include this clause, including this section (d) in all subcontracts where the subcontractor may propose publishing the results of its work under the subcontract. The contractor shall acknowledge the support of the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority whenever publicizing the work under this contract in any media by including an acknowledgement substantially as follows:

"This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract Number W911QY-20-C-0100."

H.5  Confidentiality of Information

a. Confidential information, as used in this article, means non-public information or data of a personal nature about an individual, or proprietary information or data submitted by or pertaining to an institution or organization.

b. The Contracting Officer and the Contractor may, by mutual consent, identify elsewhere in this contract specific information and/or categories of information which the Government will furnish to the Contractor or that the Contractor is expected to generate which is confidential. Similarly, the Contracting Officer and the Contractor may, by mutual consent, identify such confidential information from time to time during the performance of the contract. Failure to agree will be settled pursuant to the "Disputes" clause.

c. If it is established elsewhere in this contract that information to be utilized under this contract, or a portion thereof, is subject to the Privacy Act, the Contractor will follow the rules and procedures of disclosure set forth in the Privacy Act of 1974, 5 U.S.C. 552a, and implementing regulations and policies, with respect to systems of records determined to be subject to the Privacy Act.

d. Confidential information, as defined in paragraph (a) of this article, shall not be disclosed without the prior written consent of the individual, institution, or organization.

e. Whenever the Contractor is uncertain with regard to the proper handling of material under the contract, or if the material in question is subject to the Privacy Act or is confidential information subject to the provisions of this article, the Contractor shall obtain a written determination from the Contracting Officer prior to any release, disclosure, dissemination, or publication.

f. Contracting Officer Determinations will reflect the result of internal coordination with appropriate program and legal officials.

g. The provisions of paragraph (d) of this article shall not apply to conflicting or overlapping provisions in other Federal, State or local laws.

ALL REQUIREMENTS OF THIS SECTION H.5 MUST BE PASSED TO ALL SUB-CONTRACTOR.

H.6  Regulatory Rights

This contract involves supply of a product that requires FDA pre-market approval or clearance before commercial authorization. Contractor is seeking FDA authorization or clearance for the commercialization of mRNA-1273, Moderna vaccine for SARS-CoV-2 Coronavirus (the "Technology"). The Contractor is the Sponsor of the Regulatory Application (an investigational new drug application (IND), investigational device exemption (IDE), emergency use authorization (EUA), new drug application (NDA), biologics license application (BLA), premarket approval application (PMA), or 510(k) pre-market notification filing (510(k)) or another regulatory filing submitted to FDA) for the technology. As the Sponsor of the Regulatory Application to FDA (as the terms “sponsor” and “applicant” are defined or used in at 21 CFR §§3.2(c), 312.5, 600.3(t), 812.2(b), 812 Subpart C, or 814.20), the Contractor has certain standing before the FDA that entitles it to exclusive communications related to the Regulatory Application.
Accordingly, the Contractor and the Government agree to the following:

a. DoD Medical Product Priority. PL 115-92 allows the DoD to request, and FDA to provide, assistance to expedite development of products to diagnose, treat, or prevent serious or life-threatening diseases or conditions facing American military personnel. The contractor recognizes that only the DoD can utilize PL 115-92. As such, the contractor will work proactively with the Government to leverage this law to its maximum potential under this contract. The contractor shall submit Public Law 115-92 Sponsor Authorization Letter that will be delivered to the designated OWS POC(s) within (90) (4) of award.

H.7 Performance Based Payment Liquidated under Termination

Performance Based Payments (PBPs) have been authorized as a method of financing under this contract. In the event the Moderna’s mRNA-1273 COVID Vaccine is unsuccessful in its bid to obtain EUA or FDA approval, the Government may issue a Termination for Convenience (T4C) in whole or in part, on this contract. Upon notice of a T4C, the contractor shall submit a termination settlement proposal, IAW FAR 52.249-2, Termination for Convenience of the Government (Fixed-Price).

H.8 Public Readiness and Emergency Preparedness (PREP) Act:


(i) This Agreement is being entered into for purposes of facilitating the manufacture, testing, development, distribution, administration, and use of “Covered Countermeasures” for responding to the COVID-19 public health emergency, in accordance with Section VI of the PREP Act Declaration;

(ii) Contractor’s performance of this Agreement falls within the scope of the “Recommended Activities” for responding to the COVID-19 public health emergency, to the extent it is in accordance with Section III of the PREP Act Declaration; and

(iii) Contractor is a “Covered Person” to the extent it is a person defined in Section V of the PREP Act Declaration.
Therefore, in accordance with Sections IV and VII of the PREP Act Declaration as well as the PREP Act (42 U.S.C. § 247d-6d), the Department of Defense contracting via assisted acquisition on behalf of the HHS, expressly acknowledges and agrees that the HHS Declaration cited above, specifically its language providing immunity from suit and liability is applicable to this acquisition as long as Contractors activities fall within the terms and conditions of the PREP Act and the PREP Act Declaration.

The Government may not use, or authorize the use of, any products or materials provided under this contract, unless such use occurs in the United States (or a U.S. territory where U.S. law applies such as embassies, military and NATO installations) and is protected from liability under a declaration issued under the PREP Act, or a successor COVID-19 PREP Act Declaration of equal or greater scope. Any use where the application of the PREP Act is in question will be discussed with Moderna prior to use and, if the parties disagree on such use, the dispute will be resolved according to the “Disputes Clause” (52.233-1).

The items and technology covered by this Contract are being developed for both civil and military applications.
H.12 Transportation to Final Destination

During the course of performance under this contract, the Government may require storage of the filled drug product (FDP) before delivery to the final government location. In these circumstances, the Government will accept FDP at the contractor facility (Origin). The contractor, however, shall continue to be responsible for secure delivery of the vaccine to its final destination as identified on this contract. Regardless of where acceptance occurs, risk of loss of or damage to supplies shall remain with the contractor until delivery of FDP to a government facility.

H.13 Validation of IP/Data

The Parties acknowledge that background intellectual property and technical data assertions have been made and evaluated by the parties. The parties agree that, should additional information relevant to these assertions become available, the parties will reevaluate said assertions as necessary in the future.

H.15 Base & Option 1 Delivery Acceleration

In an effort to accelerate production of the mRNA-1273 vaccine, the Government agrees to fund eight additional drug product manufacturing slots (including fill, pack and label) within the Base Period and ten drug product manufacturing slots within the Option 1 period via a Modification to the contract. If these manufacturing slots are
successfully utilized, there will be up to 18 drug manufacturing slots funded above what was projected by Moderna and assumed within the price per dose for the doses of mRNA-1273 vaccine delivered in the Base Period and Option 1. However, because the Government is funding the additional slots within the Base and Option 1 periods in order to accelerate production, the Government is entitled to an adjustment under the conditions outlined. The Government and Moderna agree to the following:

1. If the Government exercises Option 2 (NLT 15 May):
   a. Moderna will reduce the cost of Option 2 by $1,051,000 for each successfully accelerated drug product fill under the Base Period (limited to the eight additional slots) and $819,000 for each successfully accelerated drug product fill under Option 1 (limited to the ten additional slots).

2. If the Government does not exercise Option 2 (NLT 15 May):
   a. In the event Moderna timely cancels the manufacturing slots and/or is able to otherwise fully utilize the slots originally reserved for production in the Option 2 period, Moderna agrees to credit the Government $1,051,000 for each of the eight slots and $819,000 for each of the ten slots that Moderna utilizes. In no case shall the number of drug product manufacturing slots credited exceed the number of successfully accelerated drug product manufacturing fills under the Base Period and Option 1. It is understood that Moderna will make all good-faith efforts to fill reserved slots or cancel reservations in a timely manner (i.e. within the time period required by the subcontractor).
   b. In the event that Moderna is unable to fill those reserved slots (i.e. due to lack of demand) and cancels slots, Moderna shall be entitled to recoup those reservation cancellation costs from the USG. The process is outlined as follows:
      1.) Moderna shall submit documentation to the USG of the following:
         i.) Cancellation notice to the subcontractor,
         ii.) The basis of the cancellation, and
         iii.) Cancellation fees incurred.
      2.) Moderna shall reduce credits to the USG under paragraph 2a) of this clause, IAW agreed cancellation costs incurred.
      3.) Bi-lateral agreement of the final credit shall be included in a modification to the contract. Net credit shall be deducted from final payments under the contract.

H.16 Delivery Schedule, as revised 11Feb2021 via modification P00004
For the avoidance of doubt, if the USG elects to terminate the exercised CLINs prior to acceptance and delivery in full of the required quantities of mRNA-1273, Moderna will be free to direct any unaccepted/undelivered supplies of mRNA-1273 to customers other than the USG, at its discretion, without further obligation of either party with regard to such unaccepted/undelivered supplies of mRNA-1273. The contract will be bilaterally modified to decrease the quantities by the agreed upon volume.

SECTION I - CONTRACT CLAUSES

The following have been modified:

252.232-7007 LIMITATION OF GOVERNMENT'S OBLIGATION (APR 2014)

(a) Contract line item(s) is incrementally funded. For this item, the sum of the total price is presently available for payment and allotted to this contract. An allotment schedule is set forth in paragraph (j) of this clause.

(b) For item(s) identified in paragraph (a) of this clause, the Contractor agrees to perform up to the point at which the total amount payable by the Government, including reimbursement in the event of termination of those item(s) for the Government’s convenience, approximates the total amount currently allotted to the contract. The Contractor is not authorized to continue work on those item(s) beyond that point. The Government will not be obligated in any event to reimburse the Contractor in excess of the amount allotted to the contract for those item(s) regardless of anything to the contrary in the clause entitled "TERMINATION FOR THE CONVENIENCE OF THE GOVERNMENT." As used in this clause, the total amount payable by the Government in the event of termination of applicable contract line item(s) for convenience includes costs, profit and estimated termination settlement costs for those item(s).

(c) Notwithstanding the dates specified in the allotment schedule in paragraph (j) of this clause, the Contractor will notify the Contracting Officer in writing at least ninety days prior to the date when, in the Contractor’s best judgment, the work will reach the point at which the total amount payable by the Government, including any cost for termination for convenience, will approximate 85 percent of the total amount then allotted to the contract for performance of the applicable item(s). The notification will state (1) the estimated date when that point will be reached and (2) an estimate of additional funding, if any, needed to continue performance of applicable line items up to the next scheduled date.
for allotment of funds identified in paragraph (j) of this clause, or to a mutually agreed upon substitute date. The notification will also advise the Contracting Officer of the estimated amount of additional funds that will be required for the timely performance of the item(s) funded pursuant to this clause, for subsequent period as may be specified in the allotment schedule in paragraph (j) of this clause, or otherwise agreed to by the parties. If after such notification additional funds are not allotted by the date identified in the Contractor’s notification, or by an agreed substitute date, the Contracting Officer will terminate any item(s) for which additional funds have not been allotted, pursuant to the clause of this contract entitled "TERMINATION FOR THE CONVENIENCE OF THE GOVERNMENT".

(d) When additional funds are allotted for continued performance of the contract line item(s) identified in paragraph (a) of this clause, the parties will agree as to the period of contract performance which will be covered by the funds. The provisions of paragraph (b) through (d) of this clause will apply in like manner to the additional allotted funds and agreed substitute date, and the contract will be modified accordingly.

(e) If, solely by reason of failure of the Government to allot additional funds, by the dates indicated below, in amounts sufficient for timely performance of the contract line item(s) identified in paragraph (a) of this clause, the Contractor incurs additional costs or is delayed in the performance of the work under this contract and if additional funds are allotted, an equitable adjustment will be made in the price or prices (including appropriate target, billing, and ceiling prices where applicable) of the item(s), or in the time of delivery, or both. Failure to agree to any such equitable adjustment hereunder will be a dispute concerning a question of fact within the meaning of the clause entitled "disputes."

(f) The Government may at any time prior to termination allot additional funds for the performance of the contract line item(s) identified in paragraph (a) of this clause.

(g) The termination provisions of this clause do not limit the rights of the Government under the clause entitled "DEFAULT." The provisions of this clause are limited to work and allotment of funds for the contract line item(s) set forth in paragraph (a) of this clause. This clause no longer applies once the contract if fully funded except with regard to the rights or obligations of the parties concerning equitable adjustments negotiated under paragraphs (d) or (e) of this clause.

(h) Nothing in this clause affects the right of the Government to this contract pursuant to the clause of this contract entitled "TERMINATION FOR CONVENIENCE OF THE GOVERNMENT."

(i) Nothing in this clause shall be construed as authorization of voluntary services whose acceptance is otherwise prohibited under 31 U.S.C. 1342.

(j) The parties contemplate that the Government will allot funds to this contract in accordance with the following schedule:

(b) (4)

(End of clause)
SECTION J - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS

The following have been modified:

<table>
<thead>
<tr>
<th>Document Type</th>
<th>Description</th>
<th>Page #</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exhibit A</td>
<td>CDRLs</td>
<td>15</td>
<td>11 Feb 2021</td>
</tr>
<tr>
<td>Attachment 0001</td>
<td>Supply Chain Resiliency Plan for CDRL A010</td>
<td>3</td>
<td>23 July 2020</td>
</tr>
<tr>
<td>Attachment 0002</td>
<td>b) (1) (B)</td>
<td>7</td>
<td>23 July 2020</td>
</tr>
<tr>
<td>Attachment 0003</td>
<td>b) (4)</td>
<td>Excel</td>
<td>15 July 2020</td>
</tr>
<tr>
<td>Attachment 0004</td>
<td>Data Rights</td>
<td>3</td>
<td>7 August 2020</td>
</tr>
<tr>
<td>Attachment 0005</td>
<td>b) (4)</td>
<td>2</td>
<td>7 August 2020</td>
</tr>
<tr>
<td>Attachment 0006</td>
<td>ModernaTx, Inc. Background Intellectual Property</td>
<td>3</td>
<td>6 August 2020</td>
</tr>
<tr>
<td>Attachment 0007</td>
<td>Performance Base Payment Milestone Schedule</td>
<td>2</td>
<td>7 August 2020</td>
</tr>
<tr>
<td>Attachment 0008</td>
<td>Performance Base Payment Milestone Billing Plan</td>
<td>17</td>
<td>4 December 2020</td>
</tr>
<tr>
<td>Attachment 0009</td>
<td>HRPAS Moderna Letter</td>
<td>1</td>
<td>3 September 2020</td>
</tr>
</tbody>
</table>

(End of Summary of Changes)
Supply Chain Resiliency Plan for CDRL A010

Attachment 0001

As of 23 July 2020
Supply Chain Resiliency Plan

The contractor shall provide a comprehensive Supply Chain Resiliency Plan that provides for identification and reporting of critical components associated with the secure supply of drug substance, drug product, and work-in-process through to finished goods.

1. A critical component is defined as any material that is essential to the product or the manufacturing process associated with that product. Included in the definition are consumables and disposables associated with manufacturing. NOT included in the definition are facility and capital equipment.

Consideration of critical components includes the evaluation and potential impact of raw materials, excipients, active ingredients, substances, pieces, parts, software, firmware, labeling, assembly, testing, analytical and environmental componentry, reagents, or utility materials which are used in the manufacturing of a drug, cell banks, seed stocks, devices and key processing components and equipment. A clear example of a critical component is one where a sole supplier is utilized.

2. The contractor shall identify key equipment suppliers, their locations, local resources, and the associated control processes at the time of award. This document shall address planning and scheduling for active pharmaceutical ingredients, upstream, downstream, component assembly, finished drug product and delivery events as necessary for the delivery of product.
   
   a) Communication for these requirements shall be updated as part of an annual review, or as necessary, as part of regular contractual communications.
   
   b) For upstream and downstream processing, both single-use and re-usable in-place processing equipment, and manufacturing disposables also shall be addressed. For finished goods, the inspection, labeling, packaging, and associated machinery shall be addressed taking into account capacity capabilities.
   
   c) The focus on the aspects of resiliency shall be on critical components and aspects of complying with the contractually agreed deliveries.

3. The contractor shall articulate in the plan, the methodology for inventory control, production planning, scheduling processes and ordering mechanisms, as part of those agreed deliveries.

   a) Production rates and lead times shall be understood and communicated to the HHS/ASPR/BARDA Contracting Officer or the Contracting Officer’s Representative as necessary.
   
   b) Production throughput critical constraints should be well understood by activity and by design, and communicated to contractual personnel. As necessary, communication should focus on identification, exploitation, elevation, and secondary constraints of throughput, as appropriate.

4. Reports for critical items should include the following information:

   a) Critical Material
   
   b) Primary vendor and secondary vendor, if applicable
   
   c) Supplier, Manufacturing / Distribution Location
   
   d) Supplier Lead Time
   
   e) Shelf Life
   
   f) Transportation / Shipping restrictions
g) Comparability studies, if applicable
h) Amount of material (dose equivalent) in inventory
Moderna Tx, Inc. Background Intellectual Property

Attachment 0006

As of 6 August 2020
Performance Based Payment (PBP) Milestone Schedule

Attachment 0007

As of 7 August
<table>
<thead>
<tr>
<th>CLIN</th>
<th>Milestone</th>
<th>Severable/Cumulative</th>
<th>Price</th>
<th>Milestone Completion Verification Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>001</td>
<td>Capacity and Raw Material Reservation</td>
<td>Severable</td>
<td>$601,400,000</td>
<td>Moderna shall provide: 1) written confirmation from the CMO network that sufficient capacity has been reserved; and, 2) written confirmation of reservation of sufficient raw materials along with a manufacturing schedule.</td>
</tr>
</tbody>
</table>
Performance Base Payment (PBP) Milestone Billing Plan

Attachment 0008

As of 4 December 2020
MEMORANDUM FOR Vaccine Contractor Moderna

SUBJECT: Health Resources Priorities and Allocations System (HRPAS) Rating for Department of Defense Contract W911QY20C0100

1. Department of Defense Contract #W911QY20C0100 has been rated under the Health Resources Priorities and Allocations System (HRPAS) regulation (45 C.F.R. part 101) supporting Operation Warp Speed (OWS). The purpose of this rating is to promote national defense by ensuring this contract, as well as its subcontracts, are prioritized over other orders. This means orders, including meeting delivery dates, under this contract, and supporting contracts are legally required to take precedence over other unrated orders for the same product.

2. Acceptance and rejection of rated orders (101.33). Mandatory acceptance is required unless the delivery date is at issue. If unable to meet that date, inform the Contracting Officer (CO) of the earliest date on which delivery can be made and offer to accept the order on the basis of that date. Scheduling conflicts with previously accepted lower rated or unrated orders are not sufficient reason for rejection under this section. Do not accept a DO rated order for delivery on a date which would interfere with delivery of any previously accepted DO or DX rated orders. However, you are required to notify the CO of the earliest delivery date otherwise possible. See 101.33 for justifications for Optional rejection. This is a rated order placed for the purpose of emergency response and notice of acceptance or rejection of this HRPAS priority rating is required by the CO within 48 hours.

3. You are required to place rated orders with your suppliers/subcontractors for items necessary to fulfill the requirements under this contract. You must inform suppliers/subcontractors that your orders will be prioritized over other unrated orders.

4. Supplies acquired pursuant to this rating may ONLY be used to fulfill the requirements of this contract and cannot be used for other efforts. Use of supplies acquired under the order for any other purpose will be considered a breach of the terms of this contract and subject your company to adverse contract action and remedy. In addition, violations of the provisions of the Defense Production Act may subject the offender to civil and criminal penalties, to include fines up to $10,000, imprisonment for up to one year, or both.

5. Please contact your contracting officer if you have any questions on information in this letter.

GUSTAVE F. PERNA
General, USA
Chief Operating Officer
Contract Data Requirements List (CDRL)

Exhibit A

As of 11 February 2021
1. DATA ITEM NO.  A001
2. TITLE OF DATA ITEM  Quality Audit Finding and Response Record (QAFRR)
3. SUBTITLE  BARDA Audit Findings Report

4. AUTHORITY (Data Acquisition Document No.)  DI-SESS-81923
5. CONTRACT REFERENCE  C.3.1.2.1, C.3.2.2.1, C.3.3.2.1
6. REQUIRING OFFICE  ASPR BARDA
7. DD 250 REQ NA
8. APP CODE  A
9. STATEMENT REQUIRED C
10. FREQUENCY ASREQ
11. AS OF DATE 0
12. DATE OF FIRST SUBMISSION Refer to Block 16
13. DATE OF SUBSEQUENT SUBMISSION Refer to Block 16
14. DISTRIBUTION
   a. ADDRESSEE  Draft  Final  Reg  Repro
   b. COPIES  1  1  0

15. TOTAL  1  2  0

16. REMARKS
4. The Data Item Description (DID) may be obtained from http://quicksearch.dla.mil/. The contractor shall detail the findings and corrective action(s).
8. The US Government (USG) will respond with comments or approval within 10 calendar days after receipt.
12. Submit within 10 business days of an Audit.
13. The contractor shall incorporate USG comments and provide a final report to the USG upon completion of corrective action.
14. Submit as an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA representative and the Contracting Officer (KO).

17. PRICE GROUP
18. ESTIMATED TOTAL PRICE
The public reporting burden for this collection of information is estimated to average 220 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Department of Defense, Executive Services Directorate (0704-0108). Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. Please do not return your form to the Government issuing Contracting Officer for the Contract/PR No. listed in Block E.

Please do not return your form to the above organization. Send completed form to the Government Issuing Contracting Officer for the Contract/PR No. listed in Block E.

### A. CONTRACT LINE ITEM NO.
- **0002**

### B. EXHIBIT
- **A**

### C. CATEGORY:
- **TDPL**
- **ADMIN**

### D. SYSTEM/ITEM
- **LARGE SCALE PRODUCTION OF SARS-CoV-2 VACCINE**

### E. CONTRACT/PR NO.
- **W911QY-20-C-0100**

### F. CONTRACTOR
- **Moderna US Inc.**

### G. PREPARED BY
- [Redacted]

### H. DATE
- 2/5/2021

### I. APPROVED BY
- [Redacted]

### J. DATE
- 2/5/2021

---

### 1. DATA ITEM NO.
- **A003**

### 2. TITLE OF DATA ITEM
- Contractor Furnished Material (CFM) Report

### 3. SUBTITLE
- Monthly Inventory Report

### 4. AUTHORITY (Data Acquisition Document No.)
- DI-MGMT-82049

### 5. CONTRACT REFERENCE
- C.4.1

### 6. REQUIRING OFFICE
- **ASPR BARDA**

### 7. DD 250 REQ NO
- **NO**

### 8. APP CODE
- **C**

### 9. DIST STATEMENT REQUIRED
- **MTHLY**

### 10. FREQUENCY
- **REOUIRED**

### 11. AS OF DATE
- **NA**

### 12. DATE OF FIRST SUBMISSION
- Refer to Block 16

### 13. DATE OF SUBSEQUENT SUBMISSION
- Refer to Block 16

### 14. DISTRIBUTION
- **ASPR BARDA**
  - 1
  - 1
  - 0

### 15. TOTAL
- 1
- 1
- 0

---

### 1. DATA ITEM NO.
- **A004**

### 2. TITLE OF DATA ITEM
- Research and Development of Medical Products Regulated by the U.S. Food & Drug Administration

### 3. SUBTITLE
- Quality Management Plan

### 4. AUTHORITY (Data Acquisition Document No.)
- DI-TCSP-82040 (Tailored)

### 5. CONTRACT REFERENCE
- C.4.18

### 6. REQUIRING OFFICE
- **ASPR BARDA**

### 7. DD 250 REQ NO
- **NA**

### 8. APP CODE
- **A**

### 9. DIST STATEMENT REQUIRED
- **ASREQ**

### 10. FREQUENCY
- **ASREQ**

### 11. AS OF DATE
- **0**

### 12. DATE OF FIRST SUBMISSION
- Refer to Block 16

### 13. DATE OF SUBSEQUENT SUBMISSION
- Refer to Block 16

### 14. DISTRIBUTION
- **ASPR BARDA**
  - 1
  - 1
  - 0

### 15. TOTAL
- 1
- 1
- 0

---

The Data Item Description (DID) may be obtained from http://quicksearch.dla.mil/.
**Shipping Documentation - Finished Drug Product (FDP)**

- Points of Contact information (name, title, phone, email) for manufacturing / supply chain personnel for each manufacturing, CMO, storage and distribution locations:
  - Head of Manufacturing
  - Production Planning
  - Logistics
  - Distribution
  - Labeling - Provide vaccine labeling, packaging and distribution information as soon as it becomes available. At a minimum, include the following:
  - Primary Container Information
  - Number of doses per primary container
  - Unit of Sale (carton, box, package, other)
  - Quantity per Unit of Sale: National Drug Code (NDC) or NDC-like code under EUA
  - Unit of Sale dimensions (H, W, L)
  - Unit of Sale weight
  - Intermediate Package
  - Intermediate Package dimensions
  - Intermediate Package weight
  - Quantity Unit of Sale per pallet
  - Storage Requirements
  - Stability Information

Packing List: Include the following DSCSA data elements, TI, TH and TS in packing lists. Include the contract number and CDC’s PO number (which BARDA will provide at the time the bulk order is submitted) on the packing list for all shipments. Include a copy of the MSDS (with QR code) in the packing list envelope with each shipment.

- Labeling - Provide vaccine labeling, packaging and distribution information as soon as it becomes available. At a minimum, include the following:
  - Primary Container Information
  - Number of doses per primary container
  - Unit of Sale (carton, box, package, other)
  - Quantity per Unit of Sale: National Drug Code (NDC) or NDC-like code under EUA
  - Unit of Sale dimensions (H, W, L)
  - Unit of Sale weight
  - Intermediate Package
  - Intermediate Package dimensions
  - Intermediate Package weight
  - Quantity Unit of Sale per pallet
  - Storage Requirements
  - Stability Information

Packaging List: Include the following DSCSA data elements, TI, TH and TS in packing lists. Include the contract number and CDC’s PO number (which BARDA will provide at the time the bulk order is submitted) on the packing list for all shipments. Include a copy of the MSDS (with QR code) in the packing list envelope with each shipment. Send EDI 855 Advanced Shipment Notice for all products shipped to a USG directed location. CDC will provide EDI mapping specifications that include the CDC generated PO number. Send electronic/scanned copies of all bulk shipment related documents to the COR for three-way matching on the day shipment occurs.

8. Shipping Process Demo: The US Government (USG) will respond within 15 calendar days with comments or approval. Subsequent submission (after USG approval of initial shipping process demo) within 1 calendar day after receipt of the FDP.


12. 1st Submittal (Demo): 30 calendar days prior to first shipment. Submit concurrent with each FDP delivery.

13. The contractor shall incorporate USG comments and resubmit to the USG within 1 calendar day after receipt.

14. Submit as an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) or Adobe PDF via email to the BARDA representatives and the Contracting Officer (KO), LT: Letter of Transmittal (via email).

17. PRICE GROUP

<table>
<thead>
<tr>
<th>a. ADDRESSEE</th>
<th>Draft</th>
<th>Reg</th>
<th>Final</th>
<th>Repro</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASPR BARDAM**</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>CCAP-SCN**</td>
<td>LT</td>
<td>LT</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

18. ESTIMATED TOTAL PRICE

DD FORM 1423-1, AUG 96 (EG)
### A. CONTRACT LINE ITEM NO.
- 0002

### B. EXHIBIT
- A

### C. CATEGORY:
- General/Admin Data

### D. SYSTEM/ITEM
- LARGE SCALE PRODUCTION OF SARS-COV-2 VACCINE

### E. CONTRACT/PR NO.
- W911QY-20-C-0100

### F. CONTRACTOR
- ModernaUS, Inc.

#### 1. DATA ITEM NO.
- A006

#### 2. TITLE OF DATA ITEM
- Task Directive Documentation

#### 3. SUBTITLE
- Expiring Items Report

#### 4. AUTHORITY
- DI-SESS-82206 (Tailored)

#### 5. CONTRACT REFERENCE
- C.4.3

#### 6. REQUIRING OFFICE
- ASPR BARDA

<table>
<thead>
<tr>
<th>a. ADDRESS</th>
<th>b. COPIES</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASPR BARDA*</td>
<td>0</td>
</tr>
<tr>
<td>CCAP-SCN**</td>
<td>0</td>
</tr>
</tbody>
</table>

### G. PREPARED BY
- [Redacted]

### H. DATE
- 2/5/2021

### I. APPROVED BY
- [Redacted]

### J. DATE
- 2/5/2021

---

4. The Data Item Description (DID) may be obtained from [http://quicksearch.dla.mil/](http://quicksearch.dla.mil/). Only paragraph cc applies.


13. The contractor shall incorporate USG comments and resubmit to the USG within 10 calendar days after receipt. Resubmit for any changes to key personnel.

14. Submit as an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA representative, [Redacted] and the Contracting Officer**, (KO), (b) (6)

LT: Letter of Transmittal (via email).
### REMARKS

1. The DID may be obtained from [http://quicksearch.dla.mil/](http://quicksearch.dla.mil/). The Monthly Progress report shall address each of the below items and be cross-referenced to the Statement of Work (SOW), Product Delivery Table, and an Integrated Master Schedule (IMS), and detail the following:

   - Section I - EXECUTIVE SUMMARY
   - Section II - PROGRESS
   - Section II Part A: OVERALL PROGRESS - A description of overall progress.
   - Section II Part B: MANAGEMENT AND ADMINISTRATIVE UPDATE - A description of all meetings, conference calls, etc. that have taken place during the reporting period. Include progress on administration and management issues (e.g., evaluating, and managing subcontractor performance, and personnel changes).

2. Additionally, the report shall detail the following:

   - Bulk drug substance production
   - Fill, finish, and release of product
   - Shipment of bulk substance or final product
   - Identify doses accepted by the Government in previous submissions

3. The USG will review the monthly reports with the Contractor and provide feedback with 10 calendar days after receipt.


### Instructions

12. Submit on the 20th day of the month covering the preceding month. (A Monthly progress report is not due during the month when the Final Report (final version, not draft) is due (see CDRL A009).)

13. The contractor shall incorporate USG comments and resubmit to the USG within 10 calendar days after receipt. Resubmit for any changes to key personnel.

14. Submit as an electronic file in Microsoft Office (i.e., Word, Excel, Power Point) via email to the BARDA representative and the Contracting Officer (KO).

15. Letter of Transmittal (via email).

### Approvals

- **Prepared By:**
  - (b) (6)
  - 2020

- **Approved By:**
  - (b) (6)
  - 2020

---

**DD FORM 1423-1, AUG 96 (EG)**

PREVIOUS EDITION MAY BE USED. Page 5 of 15 Pages
<table>
<thead>
<tr>
<th>DATA ITEM NO.</th>
<th>TITLE OF DATA ITEM</th>
<th>SUBTITLE</th>
<th>AUTHORITY</th>
<th>CONTRACT REFERENCE</th>
<th>STATEMENT OF WORK</th>
</tr>
</thead>
<tbody>
<tr>
<td>A010</td>
<td>Supply Chain Risk Management Plan</td>
<td>Supply Chain Resiliency Plan (SCRP)</td>
<td>DI-MGMT-82256</td>
<td>C.4.8</td>
<td>b. EXECUTIVE SUMMARY...</td>
</tr>
</tbody>
</table>

**REMARKS**

4. The Data Item Description (DID) may be obtained from http://quicksearch.dla.mil/. The final report shall be marked as Final. A cover letter with the report shall contain a summary (not to exceed 200 words) of salient results achieved during the performance of the contract and be structured in the following format: Include the following: Identify doses accepted by the Government in previous submissions.

6. The US Government (USG) will respond with comments or approval within 10 calendar days after receipt of the first draft report and within 15 calendar days of second submission.


14. Submit as an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA representative and the Contracting Officer** (KO), and the Contracting Officer** (KO),....

15. Letter of Transmittal (via email).

**DISTRIBUTION**

- **ASPR BARDA**: Draft
- **CCAP-SCN**: Draft

**TOTAL**

2 2 0

**PRICE GROUP**

17. 1

18. 1 0

**TOTAL PRICE**

0 0 0
LARGE SCALE PRODUCTION OF SARS-CoV-2

1. DATA ITEM NO. 8. APP CODE
A011 A
A012 A

2. TITLE OF DATA ITEM
Research and Development of Medical Products Regulated by the U.S. Food and Drug Administration
Research and Development of Medical Products Regulated by the U.S. Food and Drug Administration

3. SUBTITLE
Risk Management Plan (RMP)
Vendor Managed Inventory Plan/SOP

4. AUTHORITY (Data Acquisition Document No.)
DI-TCSP-82040 (Tailored)
DI-TCSP-82040 (Tailored)

5. CONTRACT REFERENCE
C.4.9
C.7.1

6. REQUIRING OFFICE
ASPR BARDA
ASPR BARDA

7. DD 250 REQ NA NA

8. APP CODE
A A

9. DIST STATEMENT REQUIRED
NA
NA

10. FREQUENCY
R/ASR
R/ASR

11. AS OF DATE
0
0

12. DATE OF FIRST SUBMISSION
Refer to Block 16
Refer to Block 16

14. DISTRIBUTION
a. ADDRESSEE
ASPR BARDA*
CCAP-SCN**

b. COPIES
1 1 0
1 1 0

17. PRICE GROUP

18. ESTIMATED TOTAL PRICE

4. The Data Item Description (DID) may be obtained from http://quicksearch.dla.mil/. Page 29, Paragraph (4) applies.
8. The US Government (USG) will respond with comments or approval within 7 calendar days after receipt.
13. The contractor shall incorporate USG comments and resubmit to the USG within 20 calendar days after receipt. Submit updates to the RMP concurrent with Monthly Progress Distribution guidance is included in DoD Instruction 5230.24.
14. Submit an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA representative; and the Contracting Officer (KO). LT: Letter of Transmittal (via email).

4. The Data Item Description (DID) may be obtained from http://quicksearch.dla.mil/. Page 29, Paragraph (4) applies. (Subparagraphs (a) through (c) do not apply.)
8. The US Government (USG) will respond with comments or approval within 7 calendar days after receipt.
12. Submit within 45 calendar days after contract award.
13. The contractor shall incorporate USG comments and resubmit to the USG within 20 calendar days after receipt. Resubmit for any changes to the USG-approved Plan/SOP.
14. Submit as an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA representative** (KO), and the Contracting Officer** (KO).

LT: Letter of Transmittal via email).

The US Government (USG) will respond with comments or approval within 7 calendar days after receipt. Submit updates to the RMP concurrent with Monthly Progress Distribution guidance is included in DoD Instruction 5230.24.

The contractor shall incorporate USG comments and resubmit to the USG within 20 calendar days after receipt. Submit updates to the RMP concurrent with Monthly Progress Distribution guidance is included in DoD Instruction 5230.24.

Submit as an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA representative, and the Contracting Officer (KO). LT: Letter of Transmittal (via email).

Submit as an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA representative, and the Contracting Officer (KO). LT: Letter of Transmittal (via email).

Submit NLT 28 February 2021.
Submit within 45 calendar days after contract award.
Submit updates to the RMP concurrent with Monthly Progress Distribution guidance is included in DoD Instruction 5230.24.
Submit as an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA representative** (KO), and the Contracting Officer* (KO). LT: Letter of Transmittal (via email).

Submit NLT 28 February 2021.
Submit within 45 calendar days after contract award.
Submit updates to the RMP concurrent with Monthly Progress Distribution guidance is included in DoD Instruction 5230.24.
Submit as an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA representative, and the Contracting Officer (KO). LT: Letter of Transmittal (via email).

Submit as an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA representative, and the Contracting Officer (KO). LT: Letter of Transmittal (via email).

Submit as an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA representative, and the Contracting Officer (KO). LT: Letter of Transmittal (via email).
The Data Item Description (DID) may be obtained from http://quicksearch.dla.mil/. (via email).

8. The US Government (USG) will respond with comments or approval within 15 business days after receipt.

9. Submit Manufacturing Reports 15 business days prior to FDA submission. Submit the Dose Tracking Template within 15 calendar days after contract award and daily thereafter.

13. The contractor shall incorporate USG comments and resubmit to the USG within 5 business days after receipt.

14. Submit an electronic file as an electronic file in Microsoft Excel via email to the BARDA representative: Marva Taylor (Marva.Taylor@hhs.gov) and the Contracting Officer** (KO).

LT: Letter of Transmittal (via email).

4. The Data Item Description (DID) may be obtained from http://quicksearch.dla.mil/. Pg 10, paragraph e applies. The contractor shall complete the Dose Tracking Template provided at Attachment 0003.

8. The US Government (USG) will respond with comments or approval within 15 business days after receipt.


12. Submit Manufacturing Reports 15 business days prior to FDA submission. Submit the Dose Tracking Template within 15 calendar days after contract award and daily thereafter.

13. The contractor shall incorporate USG comments and resubmit to the USG within 5 business days after receipt.

14. Submit an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA representative: Marva Taylor (Marva.Taylor@hhs.gov) and the Contracting Officer** (KO), Christine Sordillo (christine.f.sordillo.civ@mail.mil).

LT: Letter of Transmittal (via email).
### Contract Data Requirements List

**Form Approved**

OMB No. 0704-0188

---

**A. Contract Line Item No.**

| 0002 |

**B. Exhibit**

A

**C. Category:**

TDP

**D. System/Item**

LARGE SCALE PRODUCTION OF SARS-COV-2 VACCINE

**E. Contract/PR No.**

W911QY-20-C-0100

**F. Contractor**

ModernaUS, Inc.

---

**1. Data Item No.**

A015

**2. Title of Data Item**

NOT USED

**3. Subtitle**


**4. Authority (Data Acquisition Document No.)**

DI-MGMT-82188

**5. Contract Reference**

C-4.12

**6. Requiring Office**

ASPR BARDA

**7. DD 250 Req**

NA

**8. App Code**

A

**9. Dist Statement Required**

C

**10. Frequency**

ASREQ

**11. As of Date**

NA

**12. Date of First Submission**

Refer to Block 16

**13. Date of Subsequent Submission**

Refer to Block 16

**14. Distribution**

- **a. Addressee**
  - **ASPR BARDA**
  - **CCAP-SCN**

- **b. Copies**
  - **Draft**
  - **Final**
  - **Reg**
  - **Repro**

**15. Total**

1 1 0

---

**16. Remarks**

NOT USED

**17. Price Group**

---

**18. Estimated Total Price**

---

**4. Data Item Description (DID) may be obtained from [http://quicksearch.dla.mil/](http://quicksearch.dla.mil/).**


**12. Submit with 48 hours of activity or incident or within 24 hours for a security activity or incident.**

**13. Submit additional updates within 48 hours of additional developments. If corrective action is deemed necessary by the USG, the Contractor shall address in writing, its consideration of concerns raised within 5 business days of receipt.**

**14. Provide via telephone with written follow-ups and corrective actions to the COR and Contracting Officer. Provide write-up as an electronic file in Microsoft Office (i.e., Word, Excel, Power Point) via email to the BARDA representative and the Contracting Officer.**

**LT: Letter of Transmittal (via email).**

---

**G. Prepared By**

[Redacted]

**H. Date**

2/5/2021

**I. Approved By**

[Redacted]

**J. Date**

2/5/2021

---

DD FORM 1423-2, AUG 96

PREVIOUS EDITION MAY BE USED.
### CONTRACT DATA REQUIREMENTS LIST

#### (2 Data Items)

The public reporting burden for this collection of information is estimated to average 220 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Department of Defense, Executive Services Directorate (0704-0188). Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. Please do not return your form to the above organization. Send completed form to the Government Issuing Contracting Officer for the Contract/PR No. listed in Block E.

<table>
<thead>
<tr>
<th>A. CONTRACT LINE ITEM NO.</th>
<th>B. EXHIBIT</th>
<th>C. CATEGORY:</th>
</tr>
</thead>
<tbody>
<tr>
<td>0002</td>
<td>A</td>
<td>TDP</td>
</tr>
</tbody>
</table>

#### 1. DATA ITEM NO. A017

- **Title of Data Item:** Research and Development of Medical Products Regulated by the U.S. Food and Drug Administration
- **Subtitle:** FDA Correspondence
- **Authority:** DI-TCSP-82040 (Tailored)
- **Contract Reference:** C.4.13
- **DD 250 Req:** NA
- **Dist Statement Required:** NA
- **App Code:** A
- **Remarks:**
  - 4. The Data Item Description (DID) may be obtained from [http://quicksearch.dla.mil/](http://quicksearch.dla.mil/). Only paragraphs 3.e, 3.f, and 3.g apply.
  - 12. Submit no less than 5 business days prior to the issuance of the press release.
  - 13. Submit any final press releases no later than one (1) calendar day prior to its release.
  - 14. Submit as an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA representative, the Contracting Officer (KO), and the Contracting Officer (KO). Letter of Transmittal (via email).

#### 2. DATA ITEM NO. A018

- **Title of Data Item:** Acquisition Support Documentation
- **Subtitle:** Press Releases
- **Authority:** DI-MGMT-81607
- **Contract Reference:** C.4.14
- **DD 250 Req:** NA
- **Dist Statement Required:** NA
- **App Code:** A
- **Remarks:**
  - 4. The Data Item Description (DID) may be obtained from [http://quicksearch.dla.mil/](http://quicksearch.dla.mil/). Only paragraphs 3.e, 3.f, and 3.g apply.
  - 12. Submit no less than 5 business days prior to the issuance of the press release.
  - 13. Submit any final press releases no later than one (1) calendar day prior to its release.
  - 14. Submit as an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA representative, the Contracting Officer (KO), and the Contracting Officer (KO). Letter of Transmittal (via email).
The US Government (USG) will respond with comments or approval within 15 calendar days after receipt.


Submit within 45 calendar days after contract award.

Submit as an electronic file in Microsoft Office (i.e., Word, Excel, PowerPoint) via email to the BARDA representative and the Contracting Officer** (KO).

LT: Letter of Transmittal (via email).

The Data Item Description (DID) may be obtained from http://quicksearch.dla.mil.


Submit as an electronic file in Microsoft Office (i.e., Word, Excel, PowerPoint) via email to the BARDA representative and the Contracting Officer** (KO).

LT: Letter of Transmittal (via email).


Submit as an electronic file in Microsoft Office (i.e., Word, Excel, PowerPoint) via email to the BARDA representative and the Contracting Officer** (KO).

LT: Letter of Transmittal (via email).
# Contract Data Requirements List

The public reporting burden for this collection of information is estimated to average 220 hours per response, including the time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Department of Defense, Executive Service Directorate (0704-0188). Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. Please do not return your form to the above organization. Send completed form to the Government Issuing Contracting Officer for the Contract/PR No. listed in Block E.

## A. Contract Line Item No.

<table>
<thead>
<tr>
<th>Contract Line Item No.</th>
<th>Exhibit</th>
<th>Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>0002</td>
<td>A</td>
<td>TOP DA OTHER General/Admin Data</td>
</tr>
</tbody>
</table>

## D. System/Item

- **Large Scale Production of SARS-CoV-2 Vaccine**

## E. Contract/PR No.

W911QY-20-C-0100

## F. Contractor

Moderna US, Inc.

## L. Data Item No.

<table>
<thead>
<tr>
<th>Data Item No.</th>
<th>Title of Data Item</th>
<th>Subtitle</th>
<th>Authority</th>
<th>Contract Reference</th>
<th>Requiring Office</th>
<th>Distribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>A021</td>
<td>Report, Record of Meeting/Minutes</td>
<td>Meeting Minutes</td>
<td>DI-ADMN-81505</td>
<td>C.4.1.2, C.5.4</td>
<td>ASPR BARDA</td>
<td>Final</td>
</tr>
<tr>
<td>A022</td>
<td>Presentation Material</td>
<td>Presentation Material</td>
<td>DI-ADMN-81373</td>
<td>C.5.4</td>
<td>ASPR BARDA</td>
<td>Final</td>
</tr>
</tbody>
</table>

## G. Prepared By

(b) (6)

## H. Date

2/5/2021

## I. Approved By

( ) (6)

## J. Date

2/5/2021
### Contract Data Requirements List

**Form Approved**

**OMB No. 0704-0188**

The public reporting burden for this collection of information is estimated to average 220 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Department of Defense, Executive Services Directorate (0704-0188). Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. Please do not return your form to the above organization. Send completed form to the Government Issuing Contracting Officer for the Contract/PR No. listed in Block E.

<table>
<thead>
<tr>
<th>A. CONTRACT LINE ITEM NO.</th>
<th>B. EXHIBIT</th>
<th>C. CATEGORY:</th>
</tr>
</thead>
<tbody>
<tr>
<td>0002</td>
<td>A</td>
<td>General/Admin Data</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>D. SYSTEM/ITEM</th>
<th>E. CONTRACT/PR NO.</th>
<th>F. CONTRACTOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>LARGE SCALE PRODUCTION OF SARS-CoV-2 VACCINE</td>
<td>W911QY-20-C-0100</td>
<td>ModernaUS, Inc.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>1. DATA ITEM NO.</th>
<th>2. TITLE OF DATA ITEM</th>
<th>3. SUBTITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>A023</td>
<td>NOT USED</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. AUTHORITY (Data Acquisition Document No.)</th>
<th>5. CONTRACT REFERENCE</th>
<th>6. REQUIRING OFFICE</th>
</tr>
</thead>
<tbody>
<tr>
<td>DI-MGMT-80934C</td>
<td>C.6.3</td>
<td>ASPR BARDA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>7. DD 250 REQ</th>
<th>9. DIST STATEMENT REQUIRED</th>
<th>10. FREQUENCY</th>
<th>12. DATE OF FIRST SUBMISSION</th>
</tr>
</thead>
<tbody>
<tr>
<td>NA</td>
<td></td>
<td>ASREQ</td>
<td>Refer to Block 16</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>8. APP CODE</th>
<th>11. AS OF DATE</th>
<th>13. DATE OF SUBSEQUENT SUBMISSION</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>0</td>
<td>Refer to Block 16</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>14. DISTRIBUTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. ADDRESS</td>
</tr>
<tr>
<td>ASPR BARDA*</td>
</tr>
<tr>
<td>CCAP-SCN**</td>
</tr>
</tbody>
</table>

16. REMARKS

4. The Data Item Description (DID) may be obtained from [http://quicksearch.dla.mil/](http://quicksearch.dla.mil/).

8. The US Government (USG) will respond with comments or approval within 10 calendar days after receipt.


12. Submit within 90 calendar days of contract award.

13. The contractor shall incorporate USG comments and revisions within 10 calendar days after receipt. Resubmit for any revisions to the UGS-approved SOP/Plan.

14. Submit as an electronic file in Microsoft Office (i.e. Word, Excel, PowerPoint) via email to the BARDA representative and the Contracting Officer**(RO).**

<table>
<thead>
<tr>
<th>G. PREPARED BY</th>
<th>H. DATE</th>
<th>I. APPROVED BY</th>
<th>J. DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>[Redacted]</td>
<td>2/5/2021</td>
<td>[Redacted]</td>
<td>2/5/2021</td>
</tr>
</tbody>
</table>

DD FORM 1423-2, AUG 96

PREVIOUS EDITION MAY BE USED.
<table>
<thead>
<tr>
<th>A. CONTRACT LINE ITEM NO.</th>
<th>B. EXHIBIT</th>
<th>C. CATEGORY:</th>
<th>D. SYSTEM/ITEM</th>
<th>E. CONTRACT/PR NO.</th>
<th>F. CONTRACTOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>0002</td>
<td>A</td>
<td>TDP</td>
<td>LARGE SCALE PRODUCTION OF SARS-CoV-2 VACCINE</td>
<td>W911QY-20-C-0100</td>
<td>ModernaUS, Inc.</td>
</tr>
</tbody>
</table>

**4. AUTHORITY** (Data Acquisition Document No.): DI-TCSP-82040

**5. CONTRACT REFERENCE**: C.4.15

**6. REQUIRING OFFICE**: ASPR BARDA

**14. DISTRIBUTION**

<table>
<thead>
<tr>
<th>a. ADDRESSEE</th>
<th>b. COPIES</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASPR BARDA*</td>
<td>1 1 0</td>
</tr>
<tr>
<td>CCAP-SCN**</td>
<td>1 1 0</td>
</tr>
</tbody>
</table>

**16. REMARKS**

4. The Data Item Description (DID) may be obtained from [http://quicksearch.dla.mil/](http://quicksearch.dla.mil/).

8. The US Government (USG) will respond with comments or approval within 10 calendar days after receipt.


12. Submit within 30 calendar days of contract award.

13. The contractor shall incorporate USG comments and revisions within 10 calendar days after receipt. Resubmit for any revisions to the UGS-approved Plan.

14. Submit an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA representative and the Contracting Officer** (KO). Return Letter of Transmittal (via email).
FOR GOVERNMENT PERSONNEL

Item A. Self-explanatory.
Item B. Self-explanatory.

Item C. Mark (X) appropriate category: TDP - Technical Data Package; TM - Technical Manual; Other - other category of data, such as "Provisioning," "Configuration Management," etc.

Item D. Enter name of system/item being acquired that data will support.

Item E. Self-explanatory (to be filled in after contract award).

Item F. Self-explanatory (to be filled in after contract award).

Item G. Signature of preparer of CDRL.

Item H. Date CDRL was prepared.

Item I. Signature of CDRL approval authority.

Item J. Date CDRL was approved.

Item 1. See DoD FAR Supplement Subpart 4.71 for proper numbering.

Item 2. Enter title as it appears on data acquisition document cited in Item 4.

Item 3. Enter subtitle of data item for further definition of data item (optional entry).

Item 4. Enter Data Item Description (DID) number, military specification number, or military standard number listed in DoD 5010.12-L (AMSDL), or one-time DID number, that defines data content and format requirements.

Item 5. Enter reference to tasking in contract that generates requirement for the data item (e.g., Statement of Work paragraph number).

Item 6. Enter technical office responsible for ensuring adequacy of the data item.

Item 7. Specify requirement for inspection/acceptance of the data item by the Government.

Item 8. Specify requirement for approval of a draft before preparation of the final data item.

Item 9. For technical data, specify requirement for contractor to mark the appropriate distribution statement on the data (ref. DoDD 5230.24).

Item 10. Specify number of times data items are to be delivered.

Item 11. Specify as-of date of data item, when applicable.

Item 12. Specify when first submittal is required.

Item 13. Specify when subsequent submittals are required, when applicable.

Item 14. Enter addressees and number of draft/final copies to be delivered to each addressee. Explain reproducible copies in Item 16.

Item 15. Enter total number of draft/final copies to be delivered.

Item 16. Use for additional/clarifying information for Items 1 through 15. Examples are: Tailoring of documents cited in Item 4; Clarification of submittal dates in Items 12 and 13; Explanation of reproducible copies in Item 14; Desired medium for delivery of the data item.

FOR THE CONTRACTOR

Item 17. Specify appropriate price group from one of the following groups of effort in developing estimated prices for each data item listed on the DD Form 1423.

a. Group I. Definition - Data which is not otherwise essential to the contractor's performance of the primary contracted effort (production, development, testing, and administration) but which is required by DD Form 1423.

Estimated Price - Costs to be included under Group I are those applicable to preparing and assembling the data item in conformance with Government requirements, and the administration and other expenses related to reproducing and delivering such data items to the Government.

b. Group II. Definition - Data which is essential to the performance of the primary contracted effort but the contractor is required to perform additional work to conform to Government requirements with regard to depth of content, format, frequency of submittal, preparation, control, or quality of the data item.

Estimated Price - Costs to be included under Group II are those incurred over and above the cost of the essential data item without conforming to Government requirements, and the administrative and other expenses related to reproducing and delivering such data item to the Government.

c. Group III. Definition - Data which the contractor must develop for his internal use in performance of the primary contracted effort and does not require any substantial change to conform to Government requirements with regard to depth of content, format, frequency of submittal, preparation, control, or quality of the data item.

Estimated Price - Costs to be included under Group III are the administrative and other expenses related to reproducing and delivering such data item to the Government.

d. Group IV. Definition - Data which is developed by the contractor as part of his normal operating procedures and his effort in supplying these data to the Government is minimal.

Estimated Price - Group IV items should normally be shown on the DD Form 1423 at no cost.

Item 18. For each data item, enter an amount equal to that portion of the total price which is estimated to be attributable to the production or development for the Government of that item of data. These estimated data prices shall be developed only from those costs which will be incurred as a direct result of the requirement to supply the data, over and above those costs which would otherwise be incurred in performance of the contract if no data were required. The estimated data prices shall not include any amount for rights in data. The Government's right to use the data shall be governed by the pertinent provisions of the contract.